医薬品デリバリー市場規模、シェア、動向、2031年までの世界予測

Pharmaceutical Drug Delivery Market - Global Forecast to 2031

医薬品デリバリー市場 - 投与経路（経口、注射、局所、眼科、鼻腔、経粘膜・埋め込み、肺、経皮パッチ）、用途（がん、糖尿病、心血管疾患）、使用施設 - 2031年までの世界予測

Pharmaceutical Drug Delivery Market By Administration Route (Oral, Injectable, Topical, Ocular, Nasal, Transmucosal & Implantable, Pulmonary, Transdermal Patch), Application (Cancer, Diabetes, Cardiovascular), Facility of Use - Global Forecast to 2031

出版	MarketsandMarkets
出版年月	2026年05月
ページ数	1284
図表数	2029
価格	記載以外のライセンスについてはお問合せください
シングルユーザ	USD 4,950
種別	英文調査報告書
商品番号	SMR-20251

医薬品デリバリー市場は、2026年の2兆1,524億5,000万米ドルから2031年には2兆9,228億2,000万米ドルに成長し、予測期間中の年平均成長率（CAGR）は6.3%に達するとMarketsandMarketsでは予測しています。

この市場は、世界的な慢性疾患の増加と、生物製剤、バイオシミラー、および先進的な治療法の使用により、健全なペースで成長しています。患者に優しく自己投与可能な治療法への移行は、先進国および新興国における新しい注射剤、吸入剤、経皮剤、および標的送達システムの採用を促進しています。高分子医薬品の処方傾向は、脂質ナノ粒子、長時間作用型デポ剤、徐放性製剤、ウェアラブル注射器などの最先端の送達媒体への投資の増加につながっています。一方、デジタルおよびコネクテッド医薬品デバイス技術は、治療の精度向上、患者の服薬遵守、および患者の遠隔モニタリングを促進しています。市場の成長は、デバイスエンジニアリング、自動化、および生物学的安定化におけるイノベーションによって促進されています。しかしながら、業界は依然として、製品の開発および製造コストの高さ、より厳格なグローバル規制要件、サプライチェーンおよび滅菌に関する複雑さといった課題に直面しています。それでもなお、継続的なイノベーションと、在宅医療および患者中心のケアへの大きな動きが、世界の医薬品デリバリー市場の力強い成長を支えています。

調査概要

本レポートは、投与経路、用途、使用施設、地域別に医薬品デリバリー市場を分析しています。また、市場成長に影響を与える要因（促進要因、阻害要因、機会、課題）を考察し、市場リーダーの競争環境に関する詳細な情報を提供します。さらに、個々の成長傾向に基づき、マイクロ市場を分析しています。主要5地域（および各地域内の各国）における市場セグメントの収益予測も掲載しています。

本レポートを購入する理由

本レポートは、既存企業だけでなく新規参入企業や中小企業にとっても、市場の動向を把握し、より大きな市場シェアを獲得するための有効な手段となります。本レポートを購入した企業は、市場における存在感を強化するために、以下の戦略のいずれか、または複数の戦略を組み合わせることができます。

本レポートは、以下のポイントに関する洞察を提供します。

主要な推進要因、阻害要因、機会、課題の分析
市場浸透：医薬品デリバリー市場における主要企業が提供する製品ポートフォリオに関する包括的な情報
製品開発／イノベーション：医薬品デリバリー市場における今後のトレンド、研究開発活動、および新製品発売に関する詳細な洞察
市場開発：有望な新興地域に関する包括的な情報
市場の多様化：医薬品デリバリー市場における新製品、成長地域、および最近の動向に関する包括的な情報
競合評価：主要市場プレーヤーの市場セグメント、成長戦略、収益分析、および製品に関する詳細な評価

Report Description

The pharmaceutical drug delivery market is projected to grow from USD 2,152.45 billion in 2026 to USD 2,922.82 billion by 2031, at a CAGR of 6.3% during the forecast period. The market is growing at a healthy pace due to an increase in chronic diseases globally and the use of biologics, biosimilars, and advanced therapies. The shift towards patient-friendly and self-administration therapies is facilitating the adoption of new injectable, inhalation, transdermal, and targeted delivery systems in the developed and emerging economies. The trend of prescribing large-molecule drugs has led to a rise in investments in cutting-edge delivery vehicles such as lipid nanoparticles, long-acting depots, controlled-release formulations, and wearable injectors. Meanwhile, digital and connected drug-device technologies are facilitating greater treatment precision, patient adherence, and remote monitoring of patients. Market growth is enabled by innovations in device engineering, automation, and biologic stabilization. Nevertheless, the industry is still grappling with issues such as high costs of developing and manufacturing products, more stringent global regulatory requirements, and complexities related to the supply chain and sterility. However, continuous innovation and a significant move towards home-based and patient-centric care are still fueling strong growth in the global pharmaceutical drug delivery market.

Pharmaceutical Drug Delivery Market – Global Forecast to 2031

“Injectable drug delivery segment accounted for the largest market share in 2025”

Based on route of administration, the injectable drug delivery segment dominates the pharmaceutical drug delivery market at a global level. This is linked to the growing incidence of chronic diseases both in developed and developing countries, as well as the worldwide trend of using biologics, biosimilars, peptides, oligonucleotides, and cell & gene therapies that are only parenterally administered due to low oral bioavailability and degradation issues. Moreover, innovations in prefilled syringes, autoinjectors, wearable injectors, needles, free jet injectors, subcutaneous rapid infusion systems, and micro/nanocarrier platforms have changed the injectable drug delivery landscape completely by making drug delivery safer, more comfortable, and easier to use. These technological advances have led to a huge increase in self-administration out of the hospital and have pushed the penetration of injectable drug delivery systems in the global market much quicker.

“Hospitals segment captured the largest share of the market for formulations in 2025”

The hospital segment accounted for the largest share of the global pharmaceutical drug delivery market in 2025. Hospitals are supported by advanced infrastructure, trained clinical staff, and have the capability to manage biologics, monoclonal antibodies, radiopharmaceuticals, and other specialty treatments that require precise dosing and continuous monitoring. They offer the perfect setting for such treatments. An increased usage of large-molecule drugs has contributed to a rise in demand for sophisticated hospital-based delivery systems such as infusion pumps, long-acting injectables, nanoparticle formulations, and depot implants. Such innovative drug delivery devices and methods assist in keeping the drugs stable, ensure accurate administration, and thereby, significantly enhance the effectiveness of therapies. Worldwide regulatory bodies keep safety, device, drug compatibility, and human factor performance at the top of their priorities when it comes to hospital-administered delivery platforms. Therefore, to meet the regulations, the companies have to reinforce design, testing, and quality controls. Hospitals continue to be the most important Facility of Use in the global drug delivery landscape, as they handle more and more cases that need advanced parenteral and device-assisted therapies.

Pharmaceutical Drug Delivery Market – Global Forecast to 2031 – by region

“In 2025, North America dominated the pharmaceutical drug delivery market”

North America held the largest market share in 2025, which can be attributed to an advanced healthcare infrastructure, strong uptake of biologics and specialty medicines, and extensive R&D activity. Autoinjectors, prefilled syringes, wearable injectors, and connected drug, device platforms are adopted as a result of high chronic disease prevalence and a growing demand for self-administration in the region. The area is home to major pharmaceutical and drug, device companies that are constantly looking for new formulation technologies, high-precision injection systems, nanoparticle-based platforms, and controlled-release mechanisms. The regulatory pathways, especially the US FDA’s ones, are very supportive, and thus, combination products and biologic delivery systems help to maintain North America’s dominant position. Besides that, strong biotech clusters, research institutions, and CDMOs are also helping to create a highly innovative drug delivery ecosystem.

Breakdown of supply-side primary interviews:

By Company Type: Tier 1 (60%), Tier 2 (30%), and Tier 3 (10%)
By Designation: C-level Executives (30%), Directors (50%), and Other Designations (20%)
By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and Middle East & Africa (5%)

Breakdown of demand-side primary interviews:

By End User:

Hospitals (59%), Ambulatory Surgery Centers/Clinics (16%), Home Care Settings (15%), Diagnostic Centers (6%), and Other Facilities of Use (4%)

By Designation:

Physicians (47%), Hospital Directors and Managers (22%), Home-Care & Ambulatory Care Professionals (15%), and Other Designations (16%)

By Region:

North America (25%), Europe (24%), Asia Pacific (25%), Latin America (11%), and Middle East & Africa (15%)

Pharmaceutical Drug Delivery Market – Global Forecast to 2031 – by ecosystem

Research Coverage

This report studies the pharmaceutical drug delivery market based on route of administration, application, facility of use, and region. The report also studies factors (drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends. It forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the following strategies for strengthening their market presence.

This report provides insights into the following pointers:

Analysis of Key Drivers, Restraints, Opportunities, Challenges
Market Penetration: Comprehensive information on the product portfolios offered by the top players in the pharmaceutical drug delivery market
Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the pharmaceutical drug delivery market
Market Development: Comprehensive information on lucrative emerging regions
Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the pharmaceutical drug delivery market
Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players

1 INTRODUCTION 105
1.1 STUDY OBJECTIVES 105
1.2 MARKET DEFINITION 105
1.3 STUDY SCOPE 106
1.3.1 MARKETS COVERED 106
1.3.2 INCLUSIONS & EXCLUSIONS 107
1.3.3 YEARS CONSIDERED 108
1.3.4 CURRENCY CONSIDERED 108
1.4 MAJOR STAKEHOLDERS 109
1.5 SUMMARY OF CHANGES 109
2 EXECUTIVE SUMMARY 111
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 111
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 112
2.3 DISRUPTIVE TRENDS IN PHARMACEUTICAL DRUG DELIVERY MARKET 113
2.4 HIGH-GROWTH SEGMENTS 114
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 115
3 PREMIUM INSIGHTS 116
3.1 PHARMACEUTICAL DRUG DELIVERY MARKET OVERVIEW 116
3.2 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION & COUNTRY (2025) 117
3.3 PHARMACEUTICAL DRUG DELIVERY MARKET: REGIONAL MIX 118
3.4 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 118
3.5 PHARMACEUTICAL DRUG DELIVERY MARKET: DEVELOPED MARKETS VS.
EMERGING ECONOMIES 119
4 MARKET OVERVIEW 120
4.1 INTRODUCTION 120
4.2 MARKET DYNAMICS 120
4.2.1 DRIVERS 121
4.2.1.1 Advancements in drug delivery technologies 121
4.2.1.2 Rising burden of chronic diseases and aging population 122
4.2.1.3 Growing adoption of biologics and biosimilars 125
4.2.1.4 Growing emphasis on patient convenience 126
4.2.1.5 Increasing investments in pharmaceutical R&D 127
4.2.2 RESTRAINTS 127
4.2.2.1 Infections associated with needlestick injuries 127
4.2.2.2 Stringent government regulations 128

4.2.3 OPPORTUNITIES 129
4.2.3.1 Geographic expansion into emerging markets 129
4.2.3.2 Integration with digital health & remote monitoring 129
4.2.4 CHALLENGES 130
4.2.4.1 Pricing pressure by governing bodies 130
4.3 UNMET NEEDS & WHITE SPACES 130
4.3.1 UNMET NEEDS IN PHARMACEUTICAL DRUG DELIVERY MARKET 130
4.3.2 WHITE SPACE OPPORTUNITIES 131
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 132
4.4.1 INTERCONNECTED MARKETS 132
4.4.2 CROSS-SECTOR OPPORTUNITIES 133
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 133
4.5.1 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 133
5 INDUSTRY TRENDS 135
5.1 PORTER’S FIVE FORCES ANALYSIS 135
5.1.1 THREAT OF NEW ENTRANTS 136
5.1.2 THREAT OF SUBSTITUTES 136
5.1.3 BARGAINING POWER OF SUPPLIERS 137
5.1.4 BARGAINING POWER OF BUYERS 137
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 137
5.2 MACROECONOMIC INDICATORS 138
5.2.1 INTRODUCTION 138
5.2.2 GDP TRENDS & FORECAST 138
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 139
5.2.4 TRENDS IN GLOBAL PHARMACEUTICAL DRUG DELIVERY INDUSTRY 140
5.3 VALUE CHAIN ANALYSIS 140
5.4 ECOSYSTEM ANALYSIS 142
5.5 PRICING ANALYSIS 143
5.5.1 AVERAGE SELLING PRICE TREND OF PHARMACEUTICAL DRUG DELIVERY PRODUCTS, BY KEY PLAYER, 2023–2025 144
5.5.1.1 Average selling price trend of injectable drug delivery products,
by key player, 2023−2025 144
5.5.1.2 Average selling price trend of oral drug delivery products,
by key player, 2023−2025 145
5.5.1.3 Average selling price trend of topical drug delivery products,
by key player, 2023−2025 145
5.5.2 AVERAGE SELLING PRICE TREND OF PHARMACEUTICAL DRUG DELIVERY PRODUCTS, BY REGION, 2023–2025 146
5.5.2.1 Average selling price trend of injectable drug delivery products,
by region, 2023−2025 146
5.5.2.2 Average selling price trend of oral drug delivery products, by region, 2023−2025 147
5.5.2.3 Average selling price trend of topical drug delivery products,
by region, 2023−2025 147
5.5.2.4 Average selling price trend of pulmonary drug delivery products,
by region, 2023−2025 147
5.5.2.5 Average selling price trend of ocular drug delivery products,
by region, 2023−2025 148
5.5.2.6 Average selling price trend of nasal drug delivery products, by region, 2023−2025 148
5.6 TRADE ANALYSIS 148
5.6.1 TRADE DATA FOR HS CODE 3004 149
5.6.1.1 Import data for HS Code 3004 149
5.6.1.2 Export data for HS Code 3004 150
5.6.2 TRADE DATA FOR HS CODE 9018 150
5.6.2.1 Import data for HS Code 9018 150
5.6.2.2 Export data for HS Code 9018 151
5.7 KEY CONFERENCES & EVENTS, 2026–2027 151
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 152
5.9 INVESTMENT & FUNDING SCENARIO 153
5.10 REIMBURSEMENT ANALYSIS 154
5.11 PIPELINE ANALYSIS 155
5.12 SUCCESS STORIES & REAL-WORLD APPLICATIONS 166
5.12.1 MEDTRONIC – INSULIN PUMP DRUG DELIVERY SYSTEM 166
5.12.2 YPSOMED – SMARTPILOT CONNECTED DRUG DELIVERY 167
5.12.3 ENABLE INJECTIONS – ENFUSE CLINICAL PERFORMANCE 168
5.13 IMPACT OF US TARIFFS—PHARMACEUTICAL DRUG DELIVERY MARKET 168
5.13.1 INTRODUCTION 168
5.13.2 KEY TARIFF RATES 169
5.13.3 PRICE IMPACT ANALYSIS 170
5.13.4 IMPACT ON COUNTRIES/REGIONS 171
5.13.5 IMPACT ON END-USE INDUSTRIES 173
5.13.5.1 Impact on end-use industries: formulations 173
5.13.5.1.1 Hospitals 173
5.13.5.1.2 Ambulatory surgical centers/clinics 173
5.13.5.1.3 Home care settings 173
5.13.5.2 Impact on end-use industries: devices 173
5.13.5.2.1 Pharmaceutical companies 173
5.13.5.2.2 Biotechnology companies 174
5.13.5.2.3 Contract development and manufacturing organizations (CDMOs) & contract research organizations (CROs) 174

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 175
6.1 TECHNOLOGY ANALYSIS 175
6.1.1 KEY EMERGING TECHNOLOGIES 175
6.1.1.1 Nanotechnology-based drug delivery 175
6.1.1.2 Smart/connected drug delivery devices 175
6.1.1.3 Needle-free injection systems and microneedle patches 176
6.1.2 COMPLEMENTARY TECHNOLOGIES 177
6.1.2.1 3D printed & personalized drug delivery 177
6.1.2.2 AI/ML in drug delivery & formulation 177
6.1.3 ADJACENT TECHNOLOGIES 178
6.1.3.1 Smart monitoring, IoT, and data-driven control 178
6.1.3.2 Cell & gene delivery vectors 178
6.2 TECHNOLOGY/PRODUCT ROADMAP 179
6.2.1 NEAR-TERM (2025–2027) 179
6.2.2 MID-TERM (2028–2030) 179
6.2.3 LONG-TERM (2030+) 180
6.3 PATENT ANALYSIS 180
6.3.1 PATENT PUBLICATION TRENDS FOR PHARMACEUTICAL DRUG DELIVERY MARKET 180
6.3.2 JURISDICTION & TOP APPLICANT ANALYSIS 181
6.4 FUTURE APPLICATIONS 183
6.4.1 PATIENT-CENTRIC DRUG DELIVERY SYSTEMS 184
6.4.2 MINIMALLY INVASIVE AND SELF-ADMINISTERED DELIVERY 184
6.4.3 LONG-ACTING AND BIOLOGIC DRUG DELIVERY SYSTEMS 184
6.4.4 DIGITAL AND AI-ENABLED DRUG DELIVERY 184
6.5 IMPACT OF AI/GENERATIVE AI ON PHARMACEUTICAL DRUG DELIVERY MARKET 184
6.5.1 INTRODUCTION 184
6.5.2 MARKET POTENTIAL IN PHARMACEUTICAL DRUG DELIVERY ECOSYSTEM 185
6.5.3 AI USE CASES 185
6.5.4 KEY COMPANIES IMPLEMENTING AI IN PHARMACEUTICAL DRUG DELIVERY MARKET 186
7 SUSTAINABILITY & REGULATORY LANDSCAPE 187
7.1 REGIONAL REGULATIONS & COMPLIANCE 187
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 187
7.1.2 INDUSTRY STANDARDS 193
7.2 SUSTAINABILITY INITIATIVES 194
7.2.1 ENERGY-EFFICIENT MANUFACTURING & CARBON REDUCTION IN PHARMACEUTICAL DRUG DELIVERY 194
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 194
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 195
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 197
8.1 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 197
8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS (DEVICES) 197
8.1.2 KEY STAKEHOLDERS IN BUYING PROCESS (FORMULATIONS) 198
8.1.3 BUYING CRITERIA 198
8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 200
8.2.1 DECISION-MAKING PROCESS 200
8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES 200
8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 201
8.2.4 MARKET PROFITABILITY 202
9 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION 203
9.1 INTRODUCTION 204
9.2 INJECTABLE DRUG DELIVERY 205
9.2.1 DEVICES 207
9.2.1.1 Conventional injection devices 211
9.2.1.1.1 Rising incidence of chronic diseases and low cost of manufacturing to drive the market 211
9.2.1.1.2 Global Volume Analysis of Conventional Injection Devices, 2024-2031(Ten Thousand Units) 213
9.2.1.1.3 By material 215
9.2.1.1.3.1 Glass 215
9.2.1.1.3.2 Plastic 217
9.2.1.1.4 By usability 219
9.2.1.1.4.1 Reusable 219
9.2.1.1.4.2 Disposable 221
9.2.1.1.5 By type 223
9.2.1.1.5.1 Fillable syringes 223
9.2.1.1.6 Prefilled syringes 225
9.2.1.2 Self-injection devices 226
9.2.1.2.1 Global Volume Analysis of Self-Injection Devices, 2024-2031(Ten Thousand Units) 228
9.2.1.2.2 Needle-free injectors 229
9.2.1.2.3 Autoinjectors 231
9.2.1.2.4 Pen injectors 233
9.2.1.2.5 Wearable injectors 235
9.2.1.3 Other injectable devices 236
9.3 FORMULATIONS 238
9.3.1 BY TYPE 240
9.3.1.1 Conventional drug delivery formulations 240
9.3.1.2 Novel drug delivery formulations 243
9.3.1.3 long-acting injectable formulations 245
9.3.2 BY FORMULATION PACKAGING 246
9.3.2.1 Ampoules 247
9.3.2.1.1 Helps maintain the stability of drugs, thereby enhancing efficacy 247
9.3.2.2 Vials 249
9.3.2.2.1 Ability to store drug formulations for extensive periods 249
9.3.2.3 Cartridges 250
9.3.2.3.1 Offers higher dose accuracy and patient convenience 250
9.3.2.4 Bottles 251
9.3.2.4.1 Easy storage of solutions and emulsions drives demand 251
9.4 ORAL DRUG DELIVERY 252
9.4.1 SOLID ORAL DRUGS 254
9.4.1.1 Tablets 256
9.4.1.1.1 Development of mini-tablets is a key trend in this market segment 256
9.4.1.2 Capsules 258
9.4.1.2.1 Easy absorption of drugs and decreased irritation in GI tract drive use of capsules 258
9.4.1.3 Powders 259
9.4.1.3.1 Powders are taken by patients who are unable to swallow oral dosage forms 259
9.4.1.4 Granules 260
9.4.1.4.1 Increasing adoption of modified-release and pediatric-friendly formulations driving granules market growth 260
9.4.1.5 Lozenges 262
9.4.1.5.1 Prolonged drug release and localized action enhancing adoption of lozenges 262
9.4.2 LIQUID ORAL DRUGS 263
9.4.2.1 Syrups 265
9.4.2.1.1 Easy administration to patients with swallowing difficulties 265
9.4.2.2 Solutions 266
9.4.2.2.1 Geriatric and pediatric patients generally prefer solutions 266
9.4.2.3 Emulsions 268
9.4.2.3.1 Emulsions offer enhanced solubility and stability with ease of administration 268
9.4.2.4 Suspensions 269
9.4.2.4.1 Increasing demand for pediatric and geriatric-friendly formulations is driving the oral suspension market growth 269
9.4.2.5 Elixirs 270
9.4.2.5.1 Elixirs are a preferred choice for the pediatric population 270
9.4.3 SEMI-SOLID ORAL DRUGS 272
9.4.3.1 Gels 273
9.4.3.1.1 Gels are used for controlled drug release 273
9.4.3.2 Pastes 274
9.4.3.2.1 Microemulsions offer protection against oxidation and enzymatic hydrolysis 274
9.5 TOPICAL DRUG DELIVERY 276
9.5.1 SEMI-SOLID FORMULATIONS 278
9.5.1.1 Ointments 281
9.5.1.1.1 Ointments are widely used in analgesic indications 281
9.5.1.2 Creams 283
9.5.1.2.1 Creams are either water-in-oil or oil-in-water emulsions 283
9.5.1.3 Lotions 285
9.5.1.3.1 Easy administration of lotions to drive demand among end users 285
9.5.1.4 Gels 287
9.5.1.4.1 Faster drug release and greater patient acceptability to drive the market for topical gels 287
9.5.1.5 Pastes 289
9.5.1.5.1 Topical pastes are widely used for the treatment and prevention of skin irritation 289
9.5.2 LIQUID FORMULATIONS 290
9.5.2.1 Suspensions 292
9.5.2.1.1 Higher rate of bioavailability and controlled onset of action to drive market 292
9.5.2.2 Emulsions 294
9.5.2.2.1 Improved spreadability, stability, and controlled release of active ingredients 294
9.5.2.3 Solutions 295
9.5.2.3.1 Uniform & rapid drug delivery to boost demand 295
9.5.3 SOLID FORMULATIONS 297
9.5.3.1 Powders 299
9.5.3.1.1 Powders have a very fine particle size that covers a large surface area per unit weight 299
9.5.3.2 Suppositories 300
9.5.3.2.1 Suppositories require a suitable base to ensure the compatibility and stability of the drug 300
9.5.4 FILMS 302
9.5.4.1 Next-generation advancements to boost demand 302
9.5.5 TRANSDERMAL FORMULATIONS 304
9.5.5.1 Transdermal patches 306
9.5.5.1.1 Transdermal patches prevent premature metabolization of drugs through the liver 306
9.5.6 TRANSDERMAL GELS 308
9.5.6.1 Rapid release of drugs to fuel uptake 308
9.5.7 TRANSDERMAL SPRAYS 309
9.5.7.1 Targeted approach to boost demand 309

9.6 OCULAR DRUG DELIVERY 311
9.6.1 LIQUID FORMULATIONS 313
9.6.1.1 Eye drops 314
9.6.1.1.1 Rising prevalence of cataracts and other eye diseases to drive the market growth 314
9.6.1.2 Liquid sprays 316
9.6.1.2.1 Liquid sprays to help in overcoming drawbacks associated with traditional eye drops 316
9.6.2 SEMI-SOLID FORMULATIONS 317
9.6.2.1 Gels 319
9.6.2.1.1 High viscosity of drugs, prolonged drug release, and ease of drug administration contribute to market growth 319
9.6.2.2 Eye ointments 320
9.6.2.2.1 Eye ointments are safe to use and help in improving ocular contact time with the drug 320
9.6.3 OCULAR DEVICES 321
9.6.3.1 Drug-coated contact lenses 323
9.6.3.1.1 Better eyesight offered by lenses and high compliance to drive the market for drug-coated contact lenses 323
9.6.3.2 Ocular inserts 325
9.6.3.2.1 Ocular inserts to help in the sustained release of drugs in the eye 325
9.7 PULMONARY DRUG DELIVERY 327
9.7.1 PULMONARY DRUG DELIVERY DEVICE 329
9.7.1.1 Metered-dose Inhalers 330
9.7.1.2 Metered-dose inhalers overcome the problem of poor coordination between inhaler actuation and patient breath 330
9.7.1.2.1 Global Volume Analysis of Metered Dose Inhalers, By Region, 2024–2031 (Ten thousand units) 331
9.7.1.3 Dry Powder Inhalers 332
9.7.1.3.1 Dry powder inhaler formulations are chemically more stable than their counterparts 332
9.7.1.3.2 Global Volume Analysis of Dry Powder Inhalers, By Region, 2024–2031 (Ten thousand units) 333
9.7.1.4 Nebulizers 334
9.7.1.4.1 Global Volume Analysis of Nebulizers, By Region, 2024–2031 (Ten thousand units) 335
9.7.1.4.2 Jet nebulizers 337
9.7.1.4.2.1 Jet nebulizers account for the largest share of the nebulizers market 337
9.7.1.4.3 Ultrasonic nebulizers 338
9.7.1.4.3.1 Ultrasonic nebulizers are easy to use and comfortable to handle 338
9.7.1.4.4 Soft mist nebulizers 339
9.7.1.4.4.1 Soft mist nebulizers are preferred for the treatment of severe COPD 339
9.7.2 PULMONARY DRUG DELIVERY FORMULATION 341
9.7.2.1 Suspension Aerosol 342
9.7.2.2 Suspension Aerosols Enable Delivery of Insoluble Drug Formulations 342
9.7.2.3 Solution Aerosol 343
9.7.2.3.1 Solution Aerosols Support Uniform Drug Distribution and Formulation Flexibility 343
9.7.3 DRY POWDER FORMULATIONS 344
9.8 NASAL DRUG DELIVERY 346
9.8.1 NASAL DROPS & LIQUIDS 348
9.8.1.1 Nasal drops are considered more efficient than nasal sprays 348
9.8.2 NASAL SPRAYS 349
9.8.2.1 Nasal sprays to help in relieving nasal congestion, runny nose, itchy nose, and sneezing 349
9.8.3 NASAL POWDERS 351
9.8.3.1 Absence of preservatives and superior stability of formulations are some advantages associated with nasal powders 351
9.9 TRANSMUCOSAL DRUG DELIVERY 352
9.9.1 ORAL FORMULATIONS 354
9.9.1.1 Buccal drug delivery 356
9.9.1.1.1 Buccal drug delivery system is suitable for local and systemic therapies 356
9.9.1.2 Sublingual drug delivery 357
9.9.1.2.1 Higher rate of drug absorption compared to oral route drives adoption 357
9.9.2 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES 359
9.9.2.1 Rectal transmucosal drug delivery 360
9.9.2.1.1 Enhanced bioavailability and bypassing first-pass metabolism 360
9.9.2.2 Vaginal transmucosal drug delivery 362
9.9.2.2.1 Higher permeability and direct access to target systems drive adoption 362
9.10 IMPLANTABLE DRUG DELIVERY 363
9.10.1 ACTIVE IMPLANTABLE DRUG DELIVERY 365
9.10.1.1 Active implantable devices are used for diagnostic monitoring, body fluid transportation, and ionizing radiation 365
9.10.2 PASSIVE IMPLANTABLE DRUG DELIVERY 366
9.10.2.1 Passive implantable drug delivery systems offer a means to achieve targeted drug delivery 366
9.11 OTIC DRUG DELIVERY 368
9.11.1 EAR DROPS 369
9.11.1.1 Increasing prevalence of ear infections and demand for localized treatment are driving ear drops segment growth 369
9.11.2 OTIC SPRAYS 371
9.11.2.1 Growing demand for uniform drug distribution and improved patient convenience driving adoption 371
10 PHARMACEUTICAL DRUG DELIVERY, BY APPLICATION 373
10.1 INTRODUCTION 374
10.2 INJECTABLE DRUG DELIVERY 374
10.2.1 METABOLIC DISORDERS (DIABETES, OBESITY) 377
10.2.1.1 Rising burden of diabetes and obesity driving strong adoption of injectable drug delivery 377
10.2.2 CANCER 378
10.2.2.1 Rising prevalence of cancer and growing availability of therapeutics to drive market 378
10.2.3 IMMUNOLOGICAL & AUTOIMMUNE DISEASES 380
10.2.3.1 Increased focus on early-stage diagnosis and treatment to propel segment growth 380
10.2.4 INFECTIOUS DISEASES 381
10.2.4.1 Increasing use of liposomes to aid segment growth 381
10.2.5 OTHER INJECTABLE DRUG DELIVERY APPLICATIONS 383
10.3 ORAL DRUG DELIVERY 385
10.3.1 CARDIOVASCULAR DISEASES 387
10.3.1.1 High prevalence of CVDs and widespread use of oral therapies drive market 387
10.3.2 METABOLIC DISORDERS (DIABETES, OBESITY) 388
10.3.2.1 Growing preference for self-injection devices over traditional syringes to augment market growth 388
10.3.3 CNS DISORDERS 390
10.3.3.1 Chronic nature of CNS disorders and long-term therapy needs driving oral drug delivery adoption 390
10.3.4 INFECTIOUS DISEASES 391
10.3.4.1 High global infection burden and outpatient treatment trends driving oral drug delivery adoption 391
10.3.5 ONCOLOGY (ORAL THERAPIES) 393
10.3.5.1 Shift toward targeted therapies and at-home treatment driving oral drug delivery in oncology 393
10.3.6 OTHER ORAL DRUG DELIVERY APPLICATIONS 395
10.4 TOPICAL DRUG DELIVERY 397
10.4.1 DERMATOLOGICAL DISORDERS 399
10.4.1.1 High prevalence of skin disorders driving strong demand for topical drug delivery 399
10.4.2 PAIN MANAGEMENT 401
10.4.2.1 Localized relief and reduced systemic side-effects driving topical drug delivery in pain management 401
10.4.3 WOUND CARE 402
10.4.3.1 Rising incidence of chronic wounds and surgical procedures driving topical drug delivery in wound care 402

10.5 OCULAR DRUG DELIVERY 403
10.5.1 RETINAL DISORDERS 405
10.5.1.1 Rising prevalence of retinal diseases and biologics adoption driving growth in the retinal disorders segment 405
10.5.2 GLAUCOMA 407
10.5.2.1 High prevalence and lifelong therapy requirements driving ocular drug delivery in glaucoma 407
10.5.3 EYE INFECTIOUS DISEASES 408
10.5.3.1 High incidence of ocular infections and need for rapid localized therapy driving eye infectious diseases segment 408
10.5.4 OTHER OCULAR DRUG DELIVERY APPLICATIONS 410
10.6 PULMONARY DRUG DELIVERY 411
10.6.1 ASTHMA 413
10.6.1.1 High global asthma prevalence and lifelong inhalation therapy driving pulmonary drug delivery demand 413
10.6.2 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 415
10.6.2.1 Chronic disease burden and high reliance on inhalation therapies driving pulmonary drug delivery in COPD 415
10.6.3 PULMONARY INFECTIONS 416
10.6.3.1 High burden of respiratory infections and need for rapid drug action driving pulmonary drug delivery in pulmonary infections 416
10.6.4 OTHER PULMONARY DRUG DELIVERY APPLICATIONS 417
10.7 NASAL DRUG DELIVERY 419
10.7.1 ALLERGIC RHINITIS 420
10.7.1.1 High prevalence of allergic conditions driving nasal drug delivery in allergic rhinitis 420
10.7.2 SINUSITIS 422
10.7.2.1 High prevalence of sinus infections and need for targeted therapy driving nasal drug delivery in sinusitis 422
10.7.3 OTHER NASAL DRUG DELIVERY APPLICATIONS 423
10.8 TRANSMUCOSAL DRUG DELIVERY 424
10.8.1 PAIN MANAGEMENT 426
10.8.1.1 Rapid onset and improved patient compliance driving transmucosal drug delivery in pain management 426
10.8.2 HORMONE THERAPY 427
10.8.2.1 Need for controlled hormone delivery and long-term therapy driving transmucosal drug delivery in hormonal therapy 427
10.8.3 INFECTIOUS DISEASES 429
10.8.3.1 Targeted local therapy and improved patient compliance driving transmucosal drug delivery in infectious diseases 429
10.8.4 OTHER TRANSMUCOSAL DRUG DELIVERY APPLICATIONS 430
10.9 IMPLANTABLE DRUG DELIVERY 431
10.9.1 HORMONAL THERAPY/CONTRACEPTION 433
10.9.1.1 Long-acting reversible contraceptives and sustained hormone delivery driving market 433

10.9.2 CANCER 434
10.9.2.1 Targeted therapy and sustained drug release driving implantable drug delivery in cancer 434
10.9.3 OTHER IMPLANTABLE DRUG DELIVERY APPLICATIONS 435
10.10 OTIC DRUG DELIVERY 437
10.10.1 EAR INFECTIONS 438
10.10.1.1 High incidence of otitis and pediatric burden driving otic drug delivery in ear infections 438
10.10.2 CERUMEN REMOVAL 440
10.10.2.1 Growing demand for ear hygiene and non-invasive treatments driving otic drug delivery in cerumen removal 440
10.10.3 OTHER OTIC DRUG DELIVERY APPLICATIONS 441
11 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE 443
11.1 INTRODUCTION 444
11.2 FORMULATIONS, BY FACILITY OF USE 444
11.2.1 HOSPITALS 446
11.2.1.1 Increased hospital demand for complex drug delivery boosts market uptake 446
11.2.2 HOME CARE SETTINGS 448
11.2.2.1 Rising preference for self-administration of medicine to drive market 448
11.2.3 AMBULATORY SURGERY CENTERS/CLINICS 450
11.2.3.1 Shift toward cost-effective outpatient care driving adoption of drug delivery systems 450
11.2.4 DIAGNOSTIC CENTERS 452
11.2.4.1 Rising prevalence of chronic diseases to support market growth 452
11.2.5 LONG-TERM CARE SETTINGS 453
11.2.5.1 Growing elderly population and chronic disease burden to drive market 453
11.2.6 OTHER FACILITIES OF USE 455
11.3 DEVICES, BY FACILITY OF USE 456
11.3.1 PHARMACEUTICAL COMPANIES 458
11.3.1.1 Increasing focus on advanced drug delivery systems driving market growth 458
11.3.2 BIOTECHNOLOGY COMPANIES 460
11.3.2.1 Enabling complex biologics delivery and decentralized care 460
11.3.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS) 461
11.3.3.1 Fueling innovation through cost-effective and scalable manufacturing solutions 461
12 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION 464
12.1 INTRODUCTION 465
12.2 NORTH AMERICA 466
12.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 467
12.2.2 NORTH AMERICA: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031 469
12.2.3 US 485
12.2.3.1 US to dominate North American pharmaceutical drug delivery market 485
12.2.4 CANADA 501
12.2.4.1 Government support for research and the prevalence of chronic diseases to drive the market in Canada 501
12.3 EUROPE 518
12.3.1 EUROPE: MACROECONOMIC OUTLOOK 519
12.3.2 EUROPE: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031 519
12.3.3 GERMANY 535
12.3.3.1 Growing focus of pharmaceutical companies on the development of various drug delivery products to drive market 535
12.3.4 UK 552
12.3.4.1 NHS support and growing access to cost-effective pen needles to drive the market 552
12.3.5 FRANCE 568
12.3.5.1 Presence of leading pharmaceutical companies, along with the increasing prevalence of chronic diseases, to drive market growth in France 568
12.3.6 ITALY 584
12.3.6.1 Increasing focus on clinical research and growing popularity of branded drugs to drive demand for pharmaceutical drug manufacturing 584
12.3.7 DENMARK 600
12.3.7.1 Strong R&D ecosystem, biologics innovation, and export-driven pharmaceutical manufacturing to drive demand for pharmaceutical drug delivery 600
12.3.8 SWEDEN 616
12.3.8.1 Strong life sciences ecosystem, biologics innovation, and government-backed healthcare system to drive demand for pharmaceutical drug delivery 616
12.3.9 SPAIN 631
12.3.9.1 Increase in biologics production to support market growth 631
12.3.10 NETHERLANDS 648
12.3.10.1 Enhancing patient care through innovation and collaboration to drive market growth 648
12.3.11 REST OF EUROPE 664
12.4 ASIA PACIFIC 680
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 680
12.4.2 ASIA PACIFIC: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031 681
12.4.3 CHINA 698
12.4.3.1 A high diabetic population and rising prevalence of chronic diseases contribute to China’s large demand 698

12.4.4 JAPAN 714
12.4.4.1 Favorable government initiatives and increased geriatric population to drive market growth in Japan 714
12.4.5 INDIA 731
12.4.5.1 Growing generic demand and rising government initiatives to drive market 731
12.4.6 AUSTRALIA 747
12.4.6.1 Rising investment and a favorable tax environment to support growth 747
12.4.7 SOUTH KOREA 763
12.4.7.1 Strong government support and investments in healthcare & biopharmaceuticals to propel growth 763
12.4.8 NEW ZEALAND 779
12.4.8.1 Strong public healthcare system, rising biologics adoption, and focus on advanced therapies to drive demand 779
12.4.9 THAILAND 795
12.4.9.1 Regulatory reforms and healthcare initiatives to fuel market growth 795
12.4.10 REST OF ASIA PACIFIC 812
12.5 LATIN AMERICA 828
12.5.1 FAVORABLE COST STRUCTURE AND GOVERNMENT INVESTMENTS TO DRIVE PHARMACEUTICAL PRODUCTION IN LATAM 828
12.5.2 LATIN AMERICA: MACROECONOMIC OUTLOOK 829
12.5.3 LATIN AMERICA: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031 829
12.5.4 BRAZIL 846
12.5.4.1 Brazil attracting multinational pharmaceutical companies 846
12.5.5 MEXICO 862
12.5.5.1 Growth and diversification in Mexico’s pharmaceutical exports 862
12.5.6 ARGENTINA 878
12.5.6.1 Expanding domestic pharmaceutical production, increasing chronic disease burden, and growing biologics adoption to drive demand 878
12.5.7 REST OF LATIN AMERICA 894
12.6 MIDDLE EAST & AFRICA 910
12.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 910
12.6.2 MIDDLE EAST & AFRICA: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024–2031 911
12.6.3 GCC COUNTRIES 927
12.6.3.1 Kingdom of Saudi Arabia (KSA) 943
12.6.3.1.1 Healthcare reforms and global partnerships fuel pharmaceutical market growth 943
12.6.3.2 United Arab Emirates (UAE) 959
12.6.3.2.1 Government supports and growing local manufacturing to drive market growth 959
12.6.3.3 Rest of GCC Countries 975
12.6.4 REST OF MIDDLE EAST & AFRICA 991
13 COMPETITIVE LANDSCAPE 1008
13.1 OVERVIEW 1008
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 1008
13.3 REVENUE ANALYSIS, 2023–2025 1010
13.3.1 PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS 1010
13.3.2 PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS 1011
13.4 MARKET SHARE ANALYSIS, 2025 1011
13.4.1 GLOBAL INJECTABLE DRUG DELIVERY MANUFACTURERS 1011
13.4.1.1 Global Injectable Drug Delivery Device Manufacturers 1011
13.4.1.2 GLOBAL INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS 1014
13.4.1.2.1 US Injectable Drug Delivery Formulation Manufacturers 1016
13.4.1.3 Europe Injectable drug delivery formulation manufacturers 1017
13.4.2 GLOBAL ORAL DRUG DELIVERY MANUFACTURERS 1018
13.4.2.1 US oral drug delivery formulation manufacturers 1019
13.4.2.2 Europe oral drug delivery manufacturers 1020
13.4.3 GLOBAL TOPICAL DRUG DELIVERY MANUFACTURERS 1021
13.4.3.1 US Topical Drug Delivery Formulation Manufacturers 1022
13.4.3.2 Europe Topical Drug Delivery Manufacturers 1023
13.5 BRAND/PRODUCT COMPARISON 1025
13.6 R&D EXPENDITURE OF KEY PLAYERS 1026
13.7 COMPANY VALUATION AND FINANCIAL METRICS 1026
13.7.1 COMPANY VALUATION 1026
13.7.2 FINANCIAL METRICS 1027
13.8 COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS, 2025 1027
13.8.1 STARS 1027
13.8.2 EMERGING LEADERS 1028
13.8.3 PERVASIVE PLAYERS 1028
13.8.4 PARTICIPANTS 1028
13.8.5 COMPANY FOOTPRINT: PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS, 2025 1029
13.8.5.1 Company footprint 1029
13.8.5.2 Region footprint 1030
13.8.5.3 Product type footprint 1030
13.8.5.4 Usability footprint 1031
13.9 COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1031
13.9.1 STARS 1031
13.9.2 EMERGING LEADERS 1032
13.9.3 PERVASIVE PLAYERS 1032
13.9.4 PARTICIPANTS 1032
13.9.5 COMPANY FOOTPRINT: PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1033
13.9.5.1 Company footprint 1033
13.9.5.2 Region footprint 1034
13.9.5.3 Route of administration footprint 1035
13.9.5.4 Therapeutic application footprint 1036
13.10 COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY FORMULATION STARTUPS/SMES, 2025 1037
13.10.1 PROGRESSIVE COMPANIES 1037
13.10.2 DYNAMIC COMPANIES 1037
13.10.3 STARTING BLOCKS 1037
13.10.4 RESPONSIVE COMPANIES 1037
13.10.5 COMPETITIVE BENCHMARKING: PHARMACEUTICAL DRUG DELIVERY FORMULATION STARTUPS/SMES, 2025 1039
13.10.5.1 Detailed list of key startups/SMEs 1039
13.10.5.2 Competitive benchmarking of startups/SMEs 1039
13.11 COMPETITIVE SCENARIO 1040
13.11.1 PRODUCT APPROVALS AND LAUNCHES 1040
13.11.2 DEALS 1041
13.11.3 EXPANSIONS 1042
13.11.4 OTHER DEVELOPMENTS 1043

14 COMPANY PROFILES 1044
14.1 PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS 1044
14.1.1 JOHNSON & JOHNSON 1044
14.1.1.1 Business overview 1044
14.1.1.2 Products offered 1045
14.1.1.3 Recent developments 1047
14.1.1.3.1 Product approvals 1047
14.1.1.3.2 Deals 1054
14.1.1.3.3 Expansions 1056
14.1.1.3.4 Other developments 1056
14.1.1.4 MnM view 1057
14.1.1.4.1 Right to win 1057
14.1.1.4.2 Strategic choices 1057
14.1.1.4.3 Weaknesses and competitive threats 1057
14.1.2 NOVARTIS AG 1058
14.1.2.1 Business overview 1058
14.1.2.2 Products offered 1059
14.1.2.3 Recent developments 1062
14.1.2.3.1 Product launches & approvals 1062
14.1.2.3.2 Deals 1064
14.1.2.3.3 Expansions 1066
14.1.2.3.4 Other developments 1067
14.1.2.4 MnM view 1067
14.1.2.4.1 Right to win 1067
14.1.2.4.2 Strategic choices 1068
14.1.2.4.3 Weaknesses and competitive threats 1068
14.1.3 F. HOFFMANN-LA ROCHE LTD 1069
14.1.3.1 Business overview 1069
14.1.3.2 Products offered 1070
14.1.3.3 Recent developments 1072
14.1.3.3.1 Product launches & approvals 1072
14.1.3.3.2 Deals 1077
14.1.3.3.3 Expansions 1078
14.1.3.3.4 Other developments 1079
14.1.3.4 MnM view 1079
14.1.3.4.1 Right to win 1079
14.1.3.4.2 Strategic choices 1079
14.1.3.4.3 Weaknesses and competitive threats 1079
14.1.4 PFIZER INC. 1080
14.1.4.1 Business overview 1080
14.1.4.2 Products offered 1081
14.1.4.3 Recent developments 1087
14.1.4.3.1 Product launches & approvals 1087
14.1.4.3.2 Deals 1090
14.1.4.4 MnM view 1092
14.1.4.4.1 Right to win 1092
14.1.4.4.2 Strategic choices 1092
14.1.4.4.3 Weaknesses and competitive threats 1092
14.1.5 ELI LILLY AND COMPANY 1093
14.1.5.1 Business overview 1093
14.1.5.2 Products offered 1094
14.1.5.3 Recent developments 1095
14.1.5.3.1 Product launches & approvals 1095
14.1.5.3.2 Deals 1098
14.1.5.3.3 Expansions 1100
14.1.6 GSK PLC. 1103
14.1.6.1 Business overview 1103
14.1.6.2 Products offered 1104
14.1.6.3 Recent developments 1109
14.1.6.3.1 Product launches & approvals 1109
14.1.6.3.2 Deals 1112
14.1.6.3.3 Other developments 1115

14.1.7 ABBVIE INC. 1116
14.1.7.1 Business overview 1116
14.1.7.2 Products offered 1117
14.1.7.3 Recent developments 1121
14.1.7.3.1 Product approvals 1121
14.1.7.3.2 Deals 1123
14.1.7.3.3 Expansions 1126
14.1.7.3.4 Other developments 1127
14.1.8 MERCK & CO., INC. 1128
14.1.8.1 Business overview 1128
14.1.8.2 Products offered 1129
14.1.8.3 Recent developments 1132
14.1.8.3.1 Product launches & approvals 1132
14.1.8.3.2 Deals 1137
14.1.8.3.3 Expansions 1140
14.1.8.3.4 Other developments 1140
14.1.9 BAUSCH HEALTH COMPANIES INC. 1141
14.1.9.1 Business overview 1141
14.1.9.2 Products offered 1142
14.1.9.3 Recent developments 1145
14.1.9.3.1 Product launches & approvals 1145
14.1.9.3.2 Deals 1146
14.1.10 BAYER AG 1147
14.1.10.1 Business overview 1147
14.1.10.2 Products offered 1148
14.1.10.3 Recent developments 1150
14.1.10.3.1 Product launches & approvals 1150
14.1.10.3.2 Deals 1155
14.1.10.3.3 Expansions 1157
14.1.10.3.4 Other developments 1158
14.1.11 AMGEN INC. 1159
14.1.11.1 Business overview 1159
14.1.11.2 Products offered 1160
14.1.11.3 Recent developments 1161
14.1.11.3.1 Product launches & approvals 1161
14.1.11.3.2 Deals 1163
14.1.11.3.3 Expansions 1164
14.1.12 ASTRAZENECA 1166
14.1.12.1 Business overview 1166
14.1.12.2 Products offered 1167
14.1.12.3 Recent developments 1170
14.1.12.3.1 Product launches & approvals 1170
14.1.12.3.2 Deals 1177
14.1.12.3.3 Expansions 1178
14.1.12.3.4 Other developments 1179
14.1.13 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 1180
14.1.13.1 Business overview 1180
14.1.13.2 Products offered 1181
14.1.13.3 Recent developments 1182
14.1.13.3.1 Product launches & approvals 1182
14.1.13.3.2 Deals 1183
14.1.13.4 Recent developments 1186
14.1.13.4.1 Expansions 1186
14.2 OTHER PLAYERS 1187
14.2.1 SANOFI 1187
14.2.2 NOVO NORDISK A/S 1189
14.2.3 GLENMARK PHARMACEUTICALS LTD. 1191
14.2.4 VIATRIS INC 1195
14.2.5 BRISTOL-MYERS SQUIBB COMPANY 1197
14.2.6 RUSAN PHARMA LTD. 1199
14.2.7 CMP PHARMA, INC. 1200
14.2.8 XERIS PHARMACEUTICALS, INC. 1201
14.2.9 ADHEXPHARMA 1202
14.3 PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS 1203
14.3.1 BD 1203
14.3.1.1 Business overview 1203
14.3.1.2 Products offered 1204
14.3.1.3 Recent developments 1207
14.3.1.3.1 Deals 1207
14.3.1.3.2 Expansions 1207
14.3.1.3.3 Other developments 1208
14.3.1.4 MnM view 1208
14.3.1.4.1 Right to win 1208
14.3.1.4.2 Strategic choices 1208
14.3.1.4.3 Weaknesses and competitive threats 1208
14.3.2 CARDINAL HEALTH 1209
14.3.2.1 Business overview 1209
14.3.2.2 Products offered 1210
14.3.2.3 Recent developments 1211
14.3.2.3.1 Expansions 1211
14.3.2.4 MnM view 1211
14.3.2.4.1 Right to win 1211
14.3.2.4.2 Strategic choices 1212
14.3.2.4.3 Weaknesses and competitive threats 1212
14.3.3 B. BRAUN SE 1213
14.3.3.1 Business overview 1213
14.3.3.2 Products offered 1214
14.3.4 TERUMO CORPORATION 1216
14.3.4.1 Business overview 1216
14.3.4.2 Products offered 1217
14.3.4.3 Recent developments 1218
14.3.4.3.1 Product launches & approvals 1218
14.3.4.3.2 Expansions 1219
14.3.5 NIPRO 1220
14.3.5.1 Business overview 1220
14.3.5.2 Products offered 1221
14.3.5.3 Recent developments 1222
14.3.5.3.1 Expansions 1222
14.3.6 STEVANATO GROUP 1223
14.3.6.1 Business overview 1223
14.3.6.2 Products offered 1224
14.3.6.3 Recent developments 1225
14.3.6.3.1 Product launches & approvals 1225
14.3.6.3.2 Deals 1225
14.3.6.3.3 Expansions 1226
14.3.6.3.4 Other developments 1227
14.3.7 GERRESHEIMER AG 1228
14.3.7.1 Business overview 1228
14.3.7.2 Products offered 1229
14.3.7.3 Recent developments 1230
14.3.7.3.1 Product launches & approvals 1230
14.3.7.3.2 Deals 1231
14.3.7.3.3 Expansions 1232
14.3.8 WEST PHARMACEUTICAL SERVICES, INC. 1233
14.3.8.1 Business overview 1233
14.3.8.2 Products offered 1234
14.3.8.3 Recent developments 1235
14.3.8.3.1 Product launches & approvals 1235
14.3.8.3.2 Deals 1235
14.3.8.3.3 Expansions 1236
14.3.9 YPSOMED 1237
14.3.9.1 Business overview 1237
14.3.9.2 Products offered 1238

14.3.9.3 Recent developments 1239
14.3.9.3.1 Product launches 1239
14.3.9.3.2 Deals 1239
14.3.9.3.3 Expansions 1241
14.3.10 SHL MEDICAL AG 1242
14.3.10.1 Business overview 1242
14.3.10.2 Products offered 1242
14.3.10.3 Recent developments 1243
14.3.10.3.1 Product launches 1243
14.3.10.3.2 Deals 1244
14.3.10.3.3 Expansions 1245
15 RESEARCH METHODOLOGY 1246
15.1 RESEARCH DATA 1246
15.1.1 SECONDARY DATA 1247
15.1.1.1 Key secondary sources 1248
15.1.2 PRIMARY DATA 1248
15.1.2.1 Primary sources 1249
15.1.2.2 Key data from primary sources 1250
15.1.2.3 Key industry insights 1251
15.1.2.4 Breakdown of primaries 1251
15.2 MARKET SIZE ESTIMATION 1252
15.2.1 APPROACH 1: COMPANY REVENUE ANALYSIS APPROACH 1254
15.2.2 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION 1255
15.2.3 APPROACH 3: TOP-DOWN APPROACH 1255
15.2.4 APPROACH 4: BOTTOM-UP APPROACH 1256
15.2.5 APPROACH 4: PRIMARY INTERVIEWS 1256
15.2.6 APPROACH 5: DEMAND-SIDE APPROACH 1256
15.2.7 APPROACH 6: VOLUME DATA ANALYSIS 1257
15.3 DATA TRIANGULATION AND MARKET BREAKDOWN 1260
15.4 MARKET SHARE ASSESSMENT 1262
15.5 RESEARCH ASSUMPTIONS 1262
15.5.1 STUDY ASSUMPTIONS 1262
15.5.2 GROWTH RATE ASSUMPTIONS 1262
15.6 RISK ASSESSMENT 1263
15.6.1 RESEARCH LIMITATIONS 1263

16 APPENDIX 1264
16.1 DISCUSSION GUIDE 1264
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 1279
16.3 CUSTOMIZATION OPTIONS 1281
16.3.1 PRODUCT ANALYSIS 1281
16.3.2 COMPANY INFORMATION 1281
16.3.3 GEOGRAPHIC ANALYSIS 1281
16.3.4 COUNTRY-LEVEL VOLUME ANALYSIS BY PRODUCT 1281
16.3.5 BY ROUTE OF ADMINISTRATION MARKET SHARE ANALYSIS (TOP 5 PLAYERS) 1281
16.3.6 ANY CONSULT/CUSTOM REQUIREMENTS AS PER CLIENT REQUESTS 1281
16.4 RELATED REPORTS 1282
16.5 AUTHOR DETAILS 1283

List Of Tables

TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 108
TABLE 2 RECENT APPROVALS OF AUTOINJECTOR BIOLOGICS IN US AND EUROPE, 2024 121
TABLE 3 KEY DEVELOPMENTS IN PRE-FILLED SYRINGES AND PEN INJECTORS, 2024–2025 122
TABLE 4 TOP FIVE COUNTRIES WITH HIGHEST NUMBER OF DIABETES PATIENTS
(20–79 YEARS), 2021 VS. 2045 123
TABLE 5 KEY BIOSIMILARS/GENERICS WITH INJECTABLE DRUG DELIVERY DEVICES 125
TABLE 6 PHARMACEUTICAL DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 135
TABLE 7 GDP CHANGE, BY KEY COUNTRY, 2021–2030 (IN USD BILLION) 138
TABLE 8 AVERAGE SELLING PRICE TREND OF INJECTABLE DRUG DELIVERY PRODUCTS,
BY KEY PLAYER, 2023–2025 144
TABLE 9 AVERAGE SELLING PRICE TREND OF ORAL DRUG DELIVERY PRODUCTS,
BY KEY PLAYER, 2023–2025 145
TABLE 10 AVERAGE SELLING PRICE TREND OF TOPICAL DRUG DELIVERY PRODUCTS,
BY KEY PLAYER, 2023–2025 145
TABLE 11 AVERAGE SELLING PRICE TREND OF INJECTABLE DRUG DELIVERY PRODUCTS,
BY REGION, 2023−2025 146
TABLE 12 AVERAGE SELLING PRICE TREND OF ORAL DRUG DELIVERY PRODUCTS,
BY REGION, 2023−2025 147
TABLE 13 AVERAGE SELLING PRICE TREND OF TOPICAL DRUG DELIVERY PRODUCTS,
BY REGION, 2023−2025 147
TABLE 14 AVERAGE SELLING PRICE TREND OF PULMONARY DRUG DELIVERY PRODUCTS,
BY REGION, 2023−2025 147
TABLE 15 AVERAGE SELLING PRICE TREND OF OCULAR DRUG DELIVERY PRODUCTS,
BY REGION, 2023−2025 148
TABLE 16 AVERAGE SELLING PRICE TREND OF NASAL DRUG DELIVERY PRODUCTS,
BY REGION, 2023−2025 148
TABLE 17 IMPORT DATA FOR HS CODE 9021, BY COUNTRY, 2021–2025 (USD THOUSAND) 149
TABLE 18 EXPORT DATA FOR HS CODE 3004, BY COUNTRY, 2021–2025 (USD THOUSAND) 150
TABLE 19 IMPORT DATA FOR HS CODE 9018, BY COUNTRY, 2021–2025 (USD THOUSAND) 150
TABLE 20 EXPORT DATA FOR HS CODE 9018, BY COUNTRY, 2021–2025 (USD THOUSAND) 151
TABLE 21 PHARMACEUTICAL DRUG DELIVERY MARKET: MAJOR CONFERENCES & EVENTS IN 2026–2027 151
TABLE 22 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS (GLP-1 ANALOGUES) IN CLINICAL PIPELINE 155
TABLE 23 CASE STUDY 1: MEDTRONIC – INSULIN PUMP DRUG DELIVERY SYSTEM 166
TABLE 24 CASE STUDY 2: YPSOMED – SMARTPILOT CONNECTED DRUG DELIVERY 167
TABLE 25 CASE STUDY 3: ENABLE INJECTIONS – ENFUSE CLINICAL PERFORMANCE 168
TABLE 26 US-ADJUSTED RECIPROCAL TARIFF RATES 169
TABLE 27 KEY PRODUCT-RELATED TARIFFS EFFECTIVE PHARMACEUTICAL DRUG DELIVERY PRODUCTS 170
TABLE 28 NORTH AMERICA: IMPACT OF US TARIFFS ON CANADA 171
TABLE 29 ASIA PACIFIC: IMPACT OF US TARIFF ON CHINA, JAPAN, AND INDIA 171
TABLE 30 EUROPE: IMPACT OF US TARIFF ON GERMANY AND UK 172
TABLE 31 LATIN AMERICA: IMPACT OF US TARIFF ON MEXICO 172
TABLE 32 PHARMACEUTICAL DRUG DELIVERY MARKET: MAJOR PATENTS 182
TABLE 33 KEY COMPANIES IMPLEMENTING AI IN PHARMACEUTICAL
DRUG DELIVERY MARKET 186
TABLE 34 REGULATORY SCENARIO BY COUNTRY 187
TABLE 35 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 190
TABLE 36 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 190
TABLE 37 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 191
TABLE 38 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 192
TABLE 39 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 192
TABLE 40 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 192
TABLE 41 PHARMACEUTICAL DRUG DELIVERY MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (DEVICES) 197
TABLE 42 PHARMACEUTICAL DRUG DELIVERY MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (FORMULATIONS) 198
TABLE 43 KEY BUYING CRITERIA FOR TOP THREE END USERS 199
TABLE 44 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD BILLION) 205
TABLE 45 INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION) 206
TABLE 46 INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 206
TABLE 47 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY DEVICES 207
TABLE 48 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,
2024–2031 (USD BILLION) 209
TABLE 49 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2
024–2031 (USD BILLION) 210
TABLE 50 KEY PLAYERS PROVIDING CONVENTIONAL INJECTION DEVICES 211
TABLE 51 CONVENTIONAL INJECTION DEVICES MARKET, BY REGION,
2024–2031 (TEN THOUSAND UNITS) 213
TABLE 52 CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY,
2024–2031 (USD BILLION) 214
TABLE 53 CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,
2024–2031 (USD BILLION) 215
TABLE 54 KEY PLAYERS PROVIDING CONVENTIONAL GLASS INJECTION DEVICES 216
TABLE 55 CONVENTIONAL GLASS INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 216
TABLE 56 KEY PLAYERS PROVIDING CONVENTIONAL PLASTIC INJECTION DEVICES 217
TABLE 57 CONVENTIONAL PLASTIC INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 218
TABLE 58 CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2024–2031 (USD BILLION) 219
TABLE 59 KEY PLAYERS PROVIDING REUSABLE INJECTION DEVICES 220
TABLE 60 CONVENTIONAL REUSABLE INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 220
TABLE 61 KEY PLAYERS PROVIDING DISPOSABLE INJECTION DEVICES 221
TABLE 62 CONVENTIONAL DISPOSABLE INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 222
TABLE 63 CONVENTIONAL INJECTION DEVICES MARKET, BY TYPE, 2024–2031 (USD BILLION) 223
TABLE 64 KEY PLAYERS PROVIDING FILLABLE SYRINGES 223
TABLE 65 FILLABLE SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 224
TABLE 66 KEY PLAYERS PROVIDING PREFILLED SYRINGES 225
TABLE 67 PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 225
TABLE 68 KEY PLAYERS PROVIDING SELF-INJECTION DEVICES 226
TABLE 69 SELF-INJECTION DEVICES MARKET, BY REGION, 2024–2031 (TEN THOUSAND UNITS) 228
TABLE 70 SELF-INJECTION DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD BILLION) 228
TABLE 71 SELF-INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 228
TABLE 72 KEY PLAYERS PROVIDING NEEDLE-FREE INJECTORS 230
TABLE 73 NEEDLE-FREE INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 230
TABLE 74 KEY PLAYERS PROVIDING AUTOINJECTORS 231
TABLE 75 AUTOINJECTORS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 232
TABLE 76 KEY PLAYERS PROVIDING PEN INJECTORS 233
TABLE 77 PEN INJECTORS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 234
TABLE 78 KEY PLAYERS PROVIDING WEARABLE INJECTORS 235
TABLE 79 WEARABLE INJECTORS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 235
TABLE 80 KEY PLAYERS PROVIDING OTHER INJECTABLE DEVICES 236
TABLE 81 OTHER INJECTABLE DRUG DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 237
TABLE 82 KEY PLAYERS PROVIDING FORMULATIONS 238
TABLE 83 FORMULATIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 239
TABLE 84 FORMULATIONS MARKET, BY TYPE, 2024–2031 (USD BILLION) 240
TABLE 85 KEY PLAYERS PROVIDING CONVENTIONAL DRUG DELIVERY FORMULATIONS 241
TABLE 86 CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 242
TABLE 87 KEY PLAYERS PROVIDING NOVEL DRUG DELIVERY FORMULATIONS 243
TABLE 88 NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 244
TABLE 89 KEY PLAYERS PROVIDING LONG-ACTING FORMULATIONS 245
TABLE 90 LONG-ACTING FORMULATIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 245
TABLE 91 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2024–2031 (USD BILLION) 247
TABLE 92 INJECTABLE DRUG DELIVERY MARKET FOR AMPOULES, BY COUNTRY, 2024–2031 (USD BILLION) 248
TABLE 93 INJECTABLE DRUG DELIVERY MARKET FOR VIALS, BY COUNTRY, 2024–2031 (USD BILLION) 249
TABLE 94 INJECTABLE DRUG DELIVERY MARKET FOR CARTRIDGES, BY COUNTRY, 2024–2031 (USD BILLION) 250
TABLE 95 INJECTABLE DRUG DELIVERY MARKET FOR BOTTLES, BY COUNTRY, BY COUNTRY 2024–2031 (USD BILLION) 251
TABLE 96 ORAL DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION) 253
TABLE 97 ORAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 253
TABLE 98 ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY TYPE, 2024–2031 (USD BILLION) 255
TABLE 99 ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY COUNTRY, 2024–2031 (USD BILLION) 255
TABLE 100 TABLETS MARKET, BY REGION, 2024–2031 (USD BILLION) 257
TABLE 101 CAPSULES MARKET, BY REGION, 2024–2031 (USD BILLION) 258
TABLE 102 POWDERS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 259
TABLE 103 GRANULES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 261
TABLE 104 LOZENGES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 262
TABLE 105 ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY TYPE,
2024–2031 (USD BILLION) 264
TABLE 106 ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY COUNTRY,
2024–2031 (USD MILLION) 264
TABLE 107 ORAL SYRUPS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 265
TABLE 108 ORAL SOLUTIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 267
TABLE 109 ORAL EMULSIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 268
TABLE 110 ORAL SUSPENSIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 269
TABLE 111 ORAL ELIXIRS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 271
TABLE 112 ORAL DRUG DELIVERY MARKET FOR SEMI-SOLID DRUGS, BY TYPE,
2024–2031 (USD BILLION) 272
TABLE 113 ORAL DRUG DELIVERY MARKET FOR SEMI-SOLID DRUGS, BY COUNTRY,
2024–2031 (USD BILLION) 272
TABLE 114 ORAL GELS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 273
TABLE 115 ORAL PASTES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 275
TABLE 116 TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION) 276
TABLE 117 TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 277
TABLE 118 KEY SEMI-SOLID FORMULATIONS CURRENTLY AVAILABLE 279
TABLE 119 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2024–2031 (USD BILLION) 280
TABLE 120 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY COUNTRY, 2024–2031 (USD BILLION) 280
TABLE 121 KEY OINTMENTS CURRENTLY OFFERED 282
TABLE 122 TOPICAL OINTMENTS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 282
TABLE 123 KEY CREAMS CURRENTLY AVAILABLE 284
TABLE 124 TOPICAL CREAMS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 284
TABLE 125 KEY PLAYERS PROVIDING LOTIONS 285
TABLE 126 TOPICAL LOTIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 286
TABLE 127 KEY PLAYERS PROVIDING GELS 287
TABLE 128 TOPICAL GELS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 288
TABLE 129 KEY PASTES CURRENTLY AVAILABLE 289
TABLE 130 TOPICAL PASTES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 289
TABLE 131 KEY LIQUID FORMULATIONS CURRENTLY AVAILABLE 291
TABLE 132 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE,
2024–2031 (USD BILLION) 291
TABLE 133 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 291
TABLE 134 TOPICAL SUSPENSIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 293
TABLE 135 TOPICAL EMULSIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 294
TABLE 136 TOPICAL SOLUTIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 296
TABLE 137 KEY SOLID FORMULATIONS CURRENTLY AVAILABLE 297
TABLE 138 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE,
2024–2031 (USD BILLION) 298
TABLE 139 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 298
TABLE 140 KEY PLAYERS PROVIDING POWDERS 299
TABLE 141 TOPICAL POWDERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 299
TABLE 142 KEY PLAYERS PROVIDING SUPPOSITORIES 301
TABLE 143 TOPICAL SUPPOSITORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 301
TABLE 144 KEY PLAYERS PROVIDING FILMS 302
TABLE 145 TOPICAL FILMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 303
TABLE 146 KEY TRANSDERMAL PRODUCTS CURRENTLY AVAILABLE 304
TABLE 147 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2024–2031 (USD BILLION) 305
TABLE 148 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2024–2031 (USD BILLION) 305
TABLE 149 KEY PLAYERS PROVIDING TRANSDERMAL PATCHES 307
TABLE 150 TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 307
TABLE 151 KEY PLAYERS PROVIDING TRANSDERMAL GELS 308
TABLE 152 TRANSDERMAL GELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 308
TABLE 153 KEY PLAYERS PROVIDING TRANSDERMAL SPRAYS 310
TABLE 154 TRANSDERMAL SPRAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 310
TABLE 155 OCULAR DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION) 311
TABLE 156 OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 312
TABLE 157 OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE,
2024–2031 (USD BILLION) 313
TABLE 158 OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 313
TABLE 159 COMMERCIALLY AVAILABLE EYE DROPS 315
TABLE 160 EYE DROPS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 315
TABLE 161 LIQUID SPRAYS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 316
TABLE 162 OCULAR DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2024–2031 (USD BILLION) 317
TABLE 163 OCULAR DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 318
TABLE 164 OCULAR GELS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 319
TABLE 165 EYE OINTMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 320
TABLE 166 OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE,
2024–2031 (USD BILLION) 322
TABLE 167 OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY COUNTRY,
2024–2031 (USD BILLION) 322
TABLE 168 DRUG-COATED CONTACT LENSES MARKET, BY REGION,
2024–2031 (TEN THOUSAND UNITS) 323
TABLE 169 DRUG-COATED CONTACT LENSES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 324
TABLE 170 OCULAR INSERTS MARKET, BY REGION, 2024–2031 (TEN THOUSAND UNITS) 325
TABLE 171 OCULAR INSERTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 326
TABLE 172 PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION) 327
TABLE 173 PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 328
TABLE 174 PULMONARY DRUG DELIVERY DEVICE MARKET, BY TYPE,
2024–2031 (USD BILLION) 329
TABLE 175 PULMONARY DRUG DELIVERY DEVICE MARKET, BY COUNTRY,
2024–2031 (USD BILLION) 329
TABLE 176 PULMONARY DRUG DELIVERY MARKET FOR METERED DOSE INHALERS,
BY REGION, 2024–2031 (TEN THOUSAND UNITS) 331
TABLE 177 PULMONARY DRUG DELIVERY MARKET FOR METERED-DOSE INHALERS,
BY COUNTRY, 2024–2031 (USD BILLION) 331
TABLE 178 PULMONARY DRUG DELIVERY MARKET FOR DRY POWDER INHALERS, BY REGION, 2024–2031 (TEN THOUSAND UNITS) 333
TABLE 179 PULMONARY DRUG DELIVERY MARKET FOR DRY POWDER INHALERS,
BY COUNTRY, 2024–2031 (USD BILLION) 333
TABLE 180 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY REGION,
2024–2031 (TEN THOUSAND UNITS) 335
TABLE 181 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE,
2024–2031 (USD BILLION) 335
TABLE 182 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY COUNTRY,
2024–2031 (USD BILLION) 336
TABLE 183 JET NEBULIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 337
TABLE 184 ULTRASONIC NEBULIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 338
TABLE 185 SOFT MIST NEBULIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 339
TABLE 186 PULMONARY DRUG DELIVERY FORMULATION MARKET, BY TYPE,
2024–2031 (USD BILLION) 341
TABLE 187 PULMONARY DRUG DELIVERY FORMULATION MARKET, BY COUNTRY,
2024–2031 (USD BILLION) 341
TABLE 188 PULMONARY DRUG DELIVERY MARKET FOR SUSPENSION AEROSOL, BY COUNTRY, 2024–2031 (USD BILLION) 342
TABLE 189 PULMONARY DRUG DELIVERY MARKET FOR SOLUTION AEROSOL, BY COUNTRY, 2024–2031 (USD BILLION) 343
TABLE 190 PULMONARY DRUG DELIVERY MARKET FOR DRY POWDER FORMULATIONS,
BY COUNTRY, 2024–2031 (USD BILLION) 345
TABLE 191 NASAL DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION) 346
TABLE 192 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 347
TABLE 193 NASAL DROPS & LIQUIDS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 348
TABLE 194 NASAL SPRAYS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 350
TABLE 195 NASAL POWDERS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 351
TABLE 196 TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION) 353
TABLE 197 TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY,
2024–2031 (USD BILLION) 353
TABLE 198 TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2024–2031 (USD BILLION) 354
TABLE 199 TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS,
BY COUNTRY, 2024–2031 (USD BILLION) 355
TABLE 200 BUCCAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 356
TABLE 201 SUBLINGUAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 358
TABLE 202 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, BY TYPE, 2024–2031 (USD BILLION) 359
TABLE 203 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 359
TABLE 204 RECTAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY,
2024–2031 (USD BILLION) 361
TABLE 205 VAGINAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 362
TABLE 206 IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION) 364
TABLE 207 IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 364
TABLE 208 ACTIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 365
TABLE 209 PASSIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY,
2024–2031 (USD BILLION) 367
TABLE 210 OTIC DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION) 368
TABLE 211 OTIC DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 368
TABLE 212 OTIC DRUG DELIVERY MARKET FOR EAR DROPS, BY COUNTRY,
2024–2031 (USD MILLION) 370
TABLE 213 OTIC DRUG DELIVERY MARKET BY OTIC SPRAYS, BY COUNTRY,
2024–2031 (USD BILLION) 372
TABLE 214 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS 375
TABLE 215 INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION,
2024–2031 (USD BILLION) 375
TABLE 216 INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 376
TABLE 217 INJECTABLE DRUG DELIVERY MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD BILLION) 377
TABLE 218 INJECTABLE DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY,
2024–2031 (USD BILLION 379
TABLE 219 INJECTABLE DRUG DELIVERY MARKET FOR IMMUNOLOGICAL & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD BILLION) 380
TABLE 220 INJECTABLE DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD BILLION) 382
TABLE 221 INJECTABLE DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 384
TABLE 222 ORAL DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION) 386
TABLE 223 ORAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 386
TABLE 224 ORAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD BILLION) 387
TABLE 225 ORAL DRUG DELIVERY MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD BILLION) 389
TABLE 226 ORAL DRUG DELIVERY MARKET FOR CNS DISORDERS, BY COUNTRY,
2024–2031 (USD BILLION) 390
TABLE 227 ORAL DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,
2024–2031 (USD BILLION) 392
TABLE 228 ORAL DRUG DELIVERY MARKET FOR ONCOLOGY (ORAL THERAPIES), BY COUNTRY, 2024–2031 (USD BILLION) 394
TABLE 229 ORAL DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2024–2031 (USD BILLION) 396
TABLE 230 TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION) 398
TABLE 231 TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 398
TABLE 232 TOPICAL DRUG DELIVERY MARKET FOR DERMATOLOGICAL DISORDERS,
BY COUNTRY, 2024–2031 (USD BILLION) 400
TABLE 233 TOPICAL DRUG DELIVERY MARKET FOR PAIN MANAGEMENT, BY COUNTRY,
2024–2031 (USD BILLION) 401
TABLE 234 TOPICAL DRUG DELIVERY MARKET FOR WOUND CARE, BY COUNTRY,
2024–2031 (USD BILLION) 402
TABLE 235 OCULAR DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION 404
TABLE 236 OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 404
TABLE 237 OCULAR DRUG DELIVERY MARKET FOR RETINAL DISORDERS, BY COUNTRY,
2024–2031 (USD BILLION) 406
TABLE 238 OCULAR DRUG DELIVERY MARKET FOR GLAUCOMA, BY COUNTRY,
2024–2031 (USD BILLION) 407
TABLE 239 OCULAR DRUG DELIVERY MARKET FOR EYE INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD BILLION) 409
TABLE 240 OCULAR DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 410
TABLE 241 PULMONARY DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION 412
TABLE 242 PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 412
TABLE 243 PULMONARY DRUG DELIVERY MARKET FOR ASTHMA, BY COUNTRY,
2024–2031 (USD BILLION) 414
TABLE 244 PULMONARY DRUG DELIVERY MARKET FOR COPD, BY COUNTRY,
2024–2031 (USD BILLION) 415
TABLE 245 PULMONARY DRUG DELIVERY MARKET FOR PULMONARY INFECTIONS,
BY COUNTRY, 2024–2031 (USD BILLION) 416
TABLE 246 PULMONARY DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 418
TABLE 247 NASAL DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION) 419
TABLE 248 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 419
TABLE 249 NASAL DRUG DELIVERY MARKET FOR ALLERGIC RHINITIS, BY COUNTRY,
2024–2031 (USD BILLION) 421
TABLE 250 NASAL DRUG DELIVERY MARKET FOR SINUSITIS, BY COUNTRY,
2024–2031 (USD BILLION) 422
TABLE 251 NASAL DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2024–2031 (USD BILLION) 423
TABLE 252 TRANSMUCOSAL DRUG DELIVERY MARKET, BY APPLICATION,
2024–2031 (USD BILLION) 425
TABLE 253 TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY,
2024–2031 (USD BILLION) 425
TABLE 254 TRANSMUCOSAL DRUG DELIVERY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2024–2031 (USD BILLION) 426
TABLE 255 TRANSMUCOSAL DRUG DELIVERY MARKET FOR HORMONE THERAPY,
BY COUNTRY, 2024–2031 (USD BILLION) 428
TABLE 256 TRANSMUCOSAL DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2024–2031 (USD BILLION) 429
TABLE 257 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2024–2031 (USD BILLION) 430
TABLE 258 IMPLANTABLE DRUG DELIVERY MARKET, BY APPLICATION,
2024–2031 (USD BILLION) 432
TABLE 259 IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 432
TABLE 260 IMPLANTABLE DRUG DELIVERY MARKET FOR HORMONAL THERAPY/CONTRACEPTION, BY COUNTRY, 2024–2031 (USD BILLION) 433
TABLE 261 IMPLANTABLE DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY,
2024–2031 (USD BILLION) 435
TABLE 262 IMPLANTABLE DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 436
TABLE 263 OTIC DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION) 437
TABLE 264 OTIC DRUG DELIVERY MARKET, BY, APPLICATION, BY COUNTRY,
2024–2031 (USD BILLION) 437
TABLE 265 OTIC DRUG DELIVERY MARKET FOR EAR INFECTIONS, BY COUNTRY,
2024–2031 (USD BILLION) 439
TABLE 266 OTIC DRUG DELIVERY MARKET FOR CERUMEN REMOVAL, BY COUNTRY,
2024–2031 (USD BILLION) 440
TABLE 267 OTIC DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2024–2031 (USD BILLION) 441
TABLE 268 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2024–2031 (USD MILLION) 444
TABLE 269 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET, BY FACILITY OF USE, 2024–2031 (USD MILLION) 445
TABLE 270 FACILITY OF USE: PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 445
TABLE 271 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 447
TABLE 272 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 449
TABLE 273 PHARMACEUTICAL DRUG DELIVERY MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 451
TABLE 274 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 452
TABLE 275 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET FOR LONG-TERM CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 454
TABLE 276 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET FOR OTHER FACILITIES OF USE, BY COUNTRY, 2024–2031 (USD MILLION) 455
TABLE 277 PHARMACEUTICAL DRUG DELIVERY DEVICES MARKET, BY FACILITY OF USE,
2024–2031 (USD MILLION) 457
TABLE 278 FACILITY OF USE: PHARMACEUTICAL DRUG DELIVERY DEVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 457
TABLE 279 PHARMACEUTICAL DRUG DELIVERY DEVICES MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 459
TABLE 280 PHARMACEUTICAL DRUG DELIVERY DEVICES MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 460
TABLE 281 PHARMACEUTICAL DRUG DELIVERY DEVICES MARKET FOR CROS & CDMOS,
BY COUNTRY, 2024–2031 (USD MILLION) 462
TABLE 282 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION,
2024–2031 (USD BILLION) 466
TABLE 283 NORTH AMERICA: VOLUME ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031 (TEN THOUSAND UNITS) 469
TABLE 284 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024-2031 (USD BILLION) 469
TABLE 285 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 470
TABLE 286 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 470
TABLE 287 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 471
TABLE 288 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY MATERIAL, 2024-2031 (USD BILLION) 471
TABLE 289 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY USABILITY, 2024-2031 (USD BILLION) 471
TABLE 290 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 472
TABLE 291 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 472
TABLE 292 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 472
TABLE 293 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 473
TABLE 294 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 473
TABLE 295 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 473
TABLE 296 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 474
TABLE 297 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 474
TABLE 298 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 474
TABLE 299 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 475
TABLE 300 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 475
TABLE 301 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 475
TABLE 302 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 476
TABLE 303 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 476
TABLE 304 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 476
TABLE 305 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 477
TABLE 306 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 477
TABLE 307 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024-2031 (USD BILLION) 477
TABLE 308 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 478
TABLE 309 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 478
TABLE 310 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 478
TABLE 311 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024-2031 (USD BILLION) 479
TABLE 312 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 479
TABLE 313 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 479
TABLE 314 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 480
TABLE 315 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 480
TABLE 316 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 480
TABLE 317 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 481
TABLE 318 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 481
TABLE 319 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 481
TABLE 320 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 482
TABLE 321 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 482
TABLE 322 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 482
TABLE 323 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 483
TABLE 324 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 483
TABLE 325 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 483
TABLE 326 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 484
TABLE 327 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024-2031 (USD BILLION) 484
TABLE 328 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET,
BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER,
2024-2031 (USD BILLION) 484
TABLE 329 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 485
TABLE 330 US: KEY MACROINDICATORS 486
TABLE 331 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 486
TABLE 332 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 487
TABLE 333 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 487
TABLE 334 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY MATERIAL,
2024-2031 (USD BILLION) 487
TABLE 335 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, BY USABILITY, 2024-2031 (USD BILLION) 488
TABLE 336 US PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2024-2031 (USD BILLION) 488
TABLE 337 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 488
TABLE 338 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 489
TABLE 339 US PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY,
BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 489
TABLE 340 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY,
2024-2031 (USD BILLION) 489
TABLE 341 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 490
TABLE 342 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 490
TABLE 343 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 490
TABLE 344 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 491
TABLE 345 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 491
TABLE 346 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 491
TABLE 347 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 492
TABLE 348 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 492
TABLE 349 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 492
TABLE 350 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 493
TABLE 351 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 493
TABLE 352 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 493
TABLE 353 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES,
2024-2031 (USD BILLION) 494
TABLE 354 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 494
TABLE 355 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 494
TABLE 356 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 495

TABLE 357 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER,
2024-2031 (USD BILLION) 495
TABLE 358 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 495
TABLE 359 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 496
TABLE 360 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 496
TABLE 361 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRAN
SMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 496
TABLE 362 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 497
TABLE 363 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY,
2024-2031 (USD BILLION) 497
TABLE 364 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 497
TABLE 365 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 498
TABLE 366 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 498
TABLE 367 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 498
TABLE 368 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 499
TABLE 369 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 499
TABLE 370 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 499
TABLE 371 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 500
TABLE 372 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 500
TABLE 373 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER,
2024-2031 (USD BILLION) 500
TABLE 374 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 501
TABLE 375 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 501
TABLE 376 CANADA: KEY MACROINDICATORS 502
TABLE 377 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 503
TABLE 378 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 503
TABLE 379 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 504
TABLE 380 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 504
TABLE 381 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 504
TABLE 382 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 505
TABLE 383 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 505
TABLE 384 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 505
TABLE 385 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 506
TABLE 386 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 506
TABLE 387 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 506
TABLE 388 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 507
TABLE 389 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 507
TABLE 390 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 507
TABLE 391 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 508
TABLE 392 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 508
TABLE 393 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 508
TABLE 394 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 509
TABLE 395 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 509
TABLE 396 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 509
TABLE 397 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 510
TABLE 398 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 510
TABLE 399 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES,
2024-2031 (USD BILLION) 510
TABLE 400 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 511
TABLE 401 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 511
TABLE 402 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 511
TABLE 403 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER,
2024-2031 (USD BILLION) 512
TABLE 404 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 512
TABLE 405 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 512
TABLE 406 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 513
TABLE 407 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 513
TABLE 408 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 513
TABLE 409 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 514
TABLE 410 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 514
TABLE 411 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 514
TABLE 412 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 515
TABLE 413 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 515
TABLE 414 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 515
TABLE 415 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 516
TABLE 416 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 516
TABLE 417 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 516
TABLE 418 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 517
TABLE 419 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024-2031 (USD BILLION) 517
TABLE 420 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 517
TABLE 421 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 518
TABLE 422 EUROPE: VOLUME ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031 (TEN THOUSAND UNITS) 519
TABLE 423 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024- 2031 (USD BILLION) 520
TABLE 424 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PRODUCT, 2024- 2031 (USD BILLION) 520
TABLE 425 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 521
TABLE 426 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 521
TABLE 427 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 521
TABLE 428 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 522
TABLE 429 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 522
TABLE 430 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 522
TABLE 431 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 523
TABLE 432 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 523
TABLE 433 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 523
TABLE 434 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 524
TABLE 435 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 524
TABLE 436 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 524
TABLE 437 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 525
TABLE 438 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 525
TABLE 439 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 525
TABLE 440 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 526
TABLE 441 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 526
TABLE 442 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 526
TABLE 443 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 527
TABLE 444 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 527
TABLE 445 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 527
TABLE 446 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 528
TABLE 447 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 528
TABLE 448 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 528
TABLE 449 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 529
TABLE 450 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 529
TABLE 451 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 529
TABLE 452 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 530
TABLE 453 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 530
TABLE 454 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 530
TABLE 455 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 531
TABLE 456 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 531
TABLE 457 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 531
TABLE 458 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 532
TABLE 459 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 532
TABLE 460 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 532
TABLE 461 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 533
TABLE 462 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 533
TABLE 463 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 533
TABLE 464 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 534
TABLE 465 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 534
TABLE 466 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER,
2024- 2031 (USD BILLION) 534
TABLE 467 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 535
TABLE 468 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 535
TABLE 469 GERMANY: KEY MACROINDICATORS 537
TABLE 470 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 537
TABLE 471 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 537
TABLE 472 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 538
TABLE 473 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET,BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 538
TABLE 474 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 538
TABLE 475 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 539
TABLE 476 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 539
TABLE 477 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 539
TABLE 478 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 540
TABLE 479 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 540
TABLE 480 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 540
TABLE 481 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 541
TABLE 482 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 541
TABLE 483 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 541
TABLE 484 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 542
TABLE 485 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 542
TABLE 486 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 542
TABLE 487 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 543
TABLE 488 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 543
TABLE 489 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 543
TABLE 490 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 544
TABLE 491 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 544
TABLE 492 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 544
TABLE 493 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 545
TABLE 494 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 545
TABLE 495 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 545
TABLE 496 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 546
TABLE 497 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 546
TABLE 498 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 546
TABLE 499 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 547
TABLE 500 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 547
TABLE 501 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 547
TABLE 502 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024- 2031 (USD BILLION) 548
TABLE 503 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 548
TABLE 504 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 548
TABLE 505 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 549
TABLE 506 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 549
TABLE 507 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 549
TABLE 508 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 550
TABLE 509 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 550
TABLE 510 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 550
TABLE 511 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 551
TABLE 512 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER,
2024- 2031 (USD BILLION) 551
TABLE 513 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 551
TABLE 514 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 552
TABLE 515 KEY MARKET INDICATORS: UK 553
TABLE 516 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024- 2031 (USD BILLION) 553
TABLE 517 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024- 2031 (USD BILLION) 553
TABLE 518 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 554
TABLE 519 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 554
TABLE 520 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 554
TABLE 521 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 555
TABLE 522 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024- 2031 (USD BILLION) 555
TABLE 523 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 555
TABLE 524 UK PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY,
BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 556
TABLE 525 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY,
2024- 2031 (USD BILLION) 556
TABLE 526 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024- 2031 (USD BILLION) 556
TABLE 527 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024- 2031 (USD BILLION) 557
TABLE 528 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 557
TABLE 529 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 557
TABLE 530 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 558
TABLE 531 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 558
TABLE 532 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 558
TABLE 533 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 559
TABLE 534 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024- 2031 (USD BILLION) 559
TABLE 535 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024- 2031 (USD BILLION) 559
TABLE 536 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 560
TABLE 537 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024- 2031 (USD BILLION) 560
TABLE 538 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES,
2024- 2031 (USD BILLION) 560
TABLE 539 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024- 2031 (USD BILLION) 561
TABLE 540 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 561
TABLE 541 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 561
TABLE 542 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 562
TABLE 543 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 562
TABLE 544 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 562
TABLE 545 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 563
TABLE 546 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 563
TABLE 547 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 563
TABLE 548 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY,
2024- 2031 (USD BILLION) 564
TABLE 549 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 564
TABLE 550 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 564
TABLE 551 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 565
TABLE 552 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 565
TABLE 553 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 565
TABLE 554 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 566
TABLE 555 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 566
TABLE 556 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 566
TABLE 557 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 567
TABLE 558 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER,
2024- 2031 (USD BILLION) 567
TABLE 559 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 567
TABLE 560 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 568
TABLE 561 FRANCE: KEY MACROINDICATORS 569
TABLE 562 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 569
TABLE 563 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 569
TABLE 564 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 570
TABLE 565 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 570
TABLE 566 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 570
TABLE 567 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 571
TABLE 568 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 571
TABLE 569 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 571
TABLE 570 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 572
TABLE 571 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 572
TABLE 572 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 572
TABLE 573 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 573
TABLE 574 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 573
TABLE 575 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 573
TABLE 576 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 574
TABLE 577 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 574
TABLE 578 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 574
TABLE 579 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 575
TABLE 580 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 575
TABLE 581 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 575
TABLE 582 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 576
TABLE 583 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 576
TABLE 584 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 576
TABLE 585 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 577
TABLE 586 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 577
TABLE 587 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 577
TABLE 588 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 578
TABLE 589 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 578
TABLE 590 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 578
TABLE 591 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 579
TABLE 592 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 579
TABLE 593 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 579
TABLE 594 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024- 2031 (USD BILLION) 580
TABLE 595 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 580
TABLE 596 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 580
TABLE 597 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 581
TABLE 598 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 581
TABLE 599 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 581
TABLE 600 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 582
TABLE 601 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 582
TABLE 602 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 582
TABLE 603 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 583
TABLE 604 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER,
2024- 2031 (USD BILLION) 583
TABLE 605 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 583
TABLE 606 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 584
TABLE 607 ITALY: KEY MACROINDICATORS 585
TABLE 608 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 585
TABLE 609 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 585
TABLE 610 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 586
TABLE 611 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 586
TABLE 612 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 586
TABLE 613 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 587
TABLE 614 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024- 2031 (USD BILLION) 587
TABLE 615 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 587
TABLE 616 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 588
TABLE 617 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 588
TABLE 618 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 588
TABLE 619 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 589
TABLE 620 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 589
TABLE 621 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 589
TABLE 622 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 590
TABLE 623 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 590
TABLE 624 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 590
TABLE 625 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 591
TABLE 626 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024- 2031 (USD BILLION) 591
TABLE 627 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024- 2031 (USD BILLION) 591
TABLE 628 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 592
TABLE 629 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 592
TABLE 630 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 592
TABLE 631 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 593
TABLE 632 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 593
TABLE 633 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 593
TABLE 634 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER,
2024- 2031 (USD BILLION) 594
TABLE 635 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 594
TABLE 636 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 594
TABLE 637 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 595
TABLE 638 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 595
TABLE 639 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 595
TABLE 640 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024- 2031 (USD BILLION) 596
TABLE 641 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 596
TABLE 642 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 596
TABLE 643 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 597

TABLE 644 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 597
TABLE 645 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 597
TABLE 646 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 598
TABLE 647 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 598
TABLE 648 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 598
TABLE 649 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 599
TABLE 650 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER,
2024- 2031 (USD BILLION) 599
TABLE 651 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 599
TABLE 652 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 600
TABLE 653 DENMARK: KEY MACROINDICATORS 600
TABLE 654 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 601
TABLE 655 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 601
TABLE 656 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 601
TABLE 657 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 602
TABLE 658 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 602
TABLE 659 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 602
TABLE 660 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 603
TABLE 661 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 603
TABLE 662 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 603
TABLE 663 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 604
TABLE 664 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 604
TABLE 665 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 604
TABLE 666 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 605
TABLE 667 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 605
TABLE 668 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 605
TABLE 669 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 606
TABLE 670 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 606
TABLE 671 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 606
TABLE 672 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 607
TABLE 673 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 607
TABLE 674 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 607
TABLE 675 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 608
TABLE 676 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 608
TABLE 677 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 608
TABLE 678 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 609
TABLE 679 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 609
TABLE 680 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER,
2024- 2031 (USD BILLION) 609
TABLE 681 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 610
TABLE 682 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 610
TABLE 683 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 610
TABLE 684 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 611
TABLE 685 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 611
TABLE 686 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 611
TABLE 687 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 612
TABLE 688 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 612
TABLE 689 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 612
TABLE 690 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 613
TABLE 691 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 613
TABLE 692 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 613
TABLE 693 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 614
TABLE 694 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 614
TABLE 695 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 614
TABLE 696 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER,
2024-2031 (USD BILLION) 615
TABLE 697 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 615
TABLE 698 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 615
TABLE 699 SWEDEN: KEY MACROINDICATORS 616
TABLE 700 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 616
TABLE 701 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 617
TABLE 702 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 617
TABLE 703 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 617
TABLE 704 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 618
TABLE 705 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 618
TABLE 706 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 618
TABLE 707 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 619
TABLE 708 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 619
TABLE 709 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 619
TABLE 710 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 620
TABLE 711 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 620
TABLE 712 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 620
TABLE 713 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 621
TABLE 714 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 621
TABLE 715 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 621
TABLE 716 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 622
TABLE 717 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 622
TABLE 718 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 622
TABLE 719 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 623
TABLE 720 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 623
TABLE 721 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 623
TABLE 722 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 624
TABLE 723 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 624
TABLE 724 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 624
TABLE 725 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 625
TABLE 726 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER,
2024- 2031 (USD BILLION) 625
TABLE 727 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 625
TABLE 728 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 626
TABLE 729 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 626
TABLE 730 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 626
TABLE 731 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 627
TABLE 732 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024- 2031 (USD BILLION) 627
TABLE 733 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 627
TABLE 734 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 628
TABLE 735 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 628
TABLE 736 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 628
TABLE 737 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 629
TABLE 738 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 629
TABLE 739 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 629
TABLE 740 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 630
TABLE 741 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 630
TABLE 742 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER,
2024- 2031 (USD BILLION) 630
TABLE 743 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 631
TABLE 744 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 631
TABLE 745 SPAIN: KEY MACROINDICATORS 632
TABLE 746 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 632
TABLE 747 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 633
TABLE 748 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 633
TABLE 749 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 633
TABLE 750 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 634
TABLE 751 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 634
TABLE 752 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024- 2031 (USD BILLION) 634
TABLE 753 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 635
TABLE 754 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 635
TABLE 755 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 635
TABLE 756 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 636
TABLE 757 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 636
TABLE 758 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 636
TABLE 759 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 637
TABLE 760 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 637
TABLE 761 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 637
TABLE 762 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 638
TABLE 763 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 638
TABLE 764 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024- 2031 (USD BILLION) 638
TABLE 765 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024- 2031 (USD BILLION) 639
TABLE 766 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 639
TABLE 767 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 639
TABLE 768 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES,
2024- 2031 (USD BILLION) 640
TABLE 769 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 640
TABLE 770 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 640
TABLE 771 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 641
TABLE 772 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER,
2024- 2031 (USD BILLION) 641
TABLE 773 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 641
TABLE 774 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 642
TABLE 775 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 642
TABLE 776 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 642
TABLE 777 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 643
TABLE 778 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 643
TABLE 779 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 643
TABLE 780 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 644
TABLE 781 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 644
TABLE 782 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 644
TABLE 783 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 645
TABLE 784 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 645
TABLE 785 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 645
TABLE 786 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 646
TABLE 787 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 646
TABLE 788 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER,
2024- 2031 (USD BILLION) 646
TABLE 789 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 647
TABLE 790 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 647
TABLE 791 NETHERLANDS: KEY MACROINDICATORS 648
TABLE 792 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 649
TABLE 793 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 649
TABLE 794 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 649
TABLE 795 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET,BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 650
TABLE 796 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 650
TABLE 797 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 650
TABLE 798 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 651
TABLE 799 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 651
TABLE 800 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 651
TABLE 801 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 652
TABLE 802 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 652
TABLE 803 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 652
TABLE 804 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 653
TABLE 805 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 653
TABLE 806 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 653
TABLE 807 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 654
TABLE 808 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 654
TABLE 809 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 654
TABLE 810 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 655
TABLE 811 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 655
TABLE 812 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 655
TABLE 813 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 656
TABLE 814 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024-2031 (USD BILLION) 656
TABLE 815 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 656
TABLE 816 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 657
TABLE 817 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 657
TABLE 818 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024-2031 (USD BILLION) 657
TABLE 819 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 658
TABLE 820 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 658
TABLE 821 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 658
TABLE 822 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 659
TABLE 823 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 659
TABLE 824 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 659
TABLE 825 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 660
TABLE 826 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 660
TABLE 827 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 660
TABLE 828 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 661
TABLE 829 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 661
TABLE 830 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 661
TABLE 831 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 662
TABLE 832 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 662
TABLE 833 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 662
TABLE 834 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 663
TABLE 835 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 663
TABLE 836 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 663
TABLE 837 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 664
TABLE 838 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 665
TABLE 839 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 665
TABLE 840 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY COMPUTED TOMOGRAPHY IMAGING SYSTEMS, 2024-2031 (USD BILLION) 665
TABLE 841 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 666
TABLE 842 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 666
TABLE 843 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 666
TABLE 844 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 667
TABLE 845 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 667
TABLE 846 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 667
TABLE 847 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 668
TABLE 848 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 668
TABLE 849 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 668
TABLE 850 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 669
TABLE 851 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 669
TABLE 852 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 669
TABLE 853 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 670
TABLE 854 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 670
TABLE 855 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 670
TABLE 856 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 671
TABLE 857 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 671
TABLE 858 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 671
TABLE 859 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024-2031 (USD BILLION) 672
TABLE 860 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 672
TABLE 861 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 672
TABLE 862 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 673
TABLE 863 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 673
TABLE 864 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 673
TABLE 865 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 674
TABLE 866 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 674
TABLE 867 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 674
TABLE 868 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 675
TABLE 869 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 675
TABLE 870 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 675
TABLE 871 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 676
TABLE 872 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 676
TABLE 873 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 676
TABLE 874 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 677
TABLE 875 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 677
TABLE 876 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 677
TABLE 877 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 678
TABLE 878 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 678
TABLE 879 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 678
TABLE 880 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET,
BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER,
2024-2031 (USD BILLION) 679
TABLE 881 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 679
TABLE 882 ASIA PACIFIC: VOLUME ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031 (TEN THOUSAND UNITS) 681
TABLE 883 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY,
2024- 2031 (USD BILLION) 682
TABLE 884 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 682
TABLE 885 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 683
TABLE 886 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 683
TABLE 887 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 683
TABLE 888 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 684
TABLE 889 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 684
TABLE 890 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024- 2031 (USD BILLION) 684
TABLE 891 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 685
TABLE 892 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 685
TABLE 893 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 685
TABLE 894 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 686
TABLE 895 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 686
TABLE 896 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 686
TABLE 897 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 687
TABLE 898 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 687
TABLE 899 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 687
TABLE 900 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 688
TABLE 901 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 688
TABLE 902 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024- 2031 (USD BILLION) 688
TABLE 903 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024- 2031 (USD BILLION) 689
TABLE 904 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 689
TABLE 905 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024- 2031 (USD BILLION) 689
TABLE 906 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 690
TABLE 907 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024- 2031 (USD BILLION) 690
TABLE 908 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 690
TABLE 909 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 691
TABLE 910 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER,
2024-2031 (USD BILLION) 691
TABLE 911 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 691
TABLE 912 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 692
TABLE 913 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 692
TABLE 914 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 692
TABLE 915 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024- 2031 (USD BILLION) 693
TABLE 916 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024- 2031 (USD BILLION) 693
TABLE 917 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 693
TABLE 918 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 694
TABLE 919 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 694
TABLE 920 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 694

TABLE 921 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 695
TABLE 922 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 695
TABLE 923 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 695
TABLE 924 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 696
TABLE 925 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 696
TABLE 926 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 696
TABLE 927 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024- 2031 (USD BILLION) 697
TABLE 928 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 697
TABLE 929 CHINA: KEY MACROINDICATORS 699
TABLE 930 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 699
TABLE 931 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 699
TABLE 932 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 700
TABLE 933 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 700
TABLE 934 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 700
TABLE 935 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 701
TABLE 936 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024- 2031 (USD BILLION) 701
TABLE 937 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 701
TABLE 938 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 702
TABLE 939 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 702
TABLE 940 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 702
TABLE 941 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 703
TABLE 942 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 703
TABLE 943 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 703
TABLE 944 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 704
TABLE 945 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 704
TABLE 946 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 704
TABLE 947 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 705
TABLE 948 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024- 2031 (USD BILLION) 705
TABLE 949 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024- 2031 (USD BILLION) 705
TABLE 950 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 706
TABLE 951 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 706
TABLE 952 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES,
2024- 2031 (USD BILLION) 706
TABLE 953 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 707
TABLE 954 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 707
TABLE 955 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 707
TABLE 956 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER,
2024- 2031 (USD BILLION) 708
TABLE 957 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 708
TABLE 958 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 708
TABLE 959 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 709
TABLE 960 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 709
TABLE 961 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 709
TABLE 962 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024- 2031 (USD BILLION) 710
TABLE 963 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 710
TABLE 964 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 710
TABLE 965 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 711
TABLE 966 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 711
TABLE 967 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 711
TABLE 968 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 712
TABLE 969 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 712
TABLE 970 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 712
TABLE 971 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 713
TABLE 972 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER,
2024- 2031 (USD BILLION) 713
TABLE 973 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 713
TABLE 974 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 714
TABLE 975 JAPAN: KEY MACROINDICATORS 715
TABLE 976 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PRODUCT,
2024- 2031 (USD BILLION) 716
TABLE 977 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 716
TABLE 978 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 716
TABLE 979 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 717
TABLE 980 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 717
TABLE 981 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 717
TABLE 982 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024- 2031 (USD BILLION) 718
TABLE 983 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 718
TABLE 984 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 718
TABLE 985 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 719
TABLE 986 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 719
TABLE 987 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 719
TABLE 988 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 720
TABLE 989 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 720
TABLE 990 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 720
TABLE 991 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 721
TABLE 992 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 721
TABLE 993 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 721
TABLE 994 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024- 2031 (USD BILLION) 722
TABLE 995 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024- 2031 (USD BILLION) 722
TABLE 996 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 722
TABLE 997 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 723
TABLE 998 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 723
TABLE 999 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 723
TABLE 1000 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 724
TABLE 1001 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 724
TABLE 1002 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER,
2024- 2031 (USD BILLION) 724
TABLE 1003 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 725
TABLE 1004 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 725
TABLE 1005 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 725
TABLE 1006 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 726
TABLE 1007 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 726
TABLE 1008 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 726
TABLE 1009 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 727
TABLE 1010 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 727
TABLE 1011 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 727
TABLE 1012 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 728
TABLE 1013 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 728
TABLE 1014 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 728
TABLE 1015 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 729
TABLE 1016 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 729
TABLE 1017 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 729
TABLE 1018 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER,
2024- 2031 (USD BILLION) 730
TABLE 1019 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 730
TABLE 1020 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 730
TABLE 1021 INDIA: KEY MACROINDICATORS 731
TABLE 1022 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 732
TABLE 1023 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 732
TABLE 1024 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 732
TABLE 1025 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 733
TABLE 1026 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 733
TABLE 1027 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 733
TABLE 1028 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024- 2031 (USD BILLION) 734
TABLE 1029 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 734
TABLE 1030 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 734
TABLE 1031 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 735
TABLE 1032 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 735
TABLE 1033 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 735
TABLE 1034 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 736
TABLE 1035 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 736
TABLE 1036 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 736
TABLE 1037 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 737
TABLE 1038 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 737
TABLE 1039 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 737
TABLE 1040 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024- 2031 (USD BILLION) 738
TABLE 1041 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024- 2031 (USD BILLION) 738
TABLE 1042 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 738
TABLE 1043 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 739
TABLE 1044 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES,
2024- 2031 (USD BILLION) 739
TABLE 1045 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 739
TABLE 1046 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 740
TABLE 1047 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 740
TABLE 1048 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER,
2024- 2031 (USD BILLION) 740
TABLE 1049 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 741
TABLE 1050 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 741
TABLE 1051 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 741
TABLE 1052 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 742
TABLE 1053 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 742
TABLE 1054 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024- 2031 (USD BILLION) 742
TABLE 1055 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 743
TABLE 1056 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 743
TABLE 1057 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 744
TABLE 1058 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 744
TABLE 1059 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 744
TABLE 1060 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 745
TABLE 1061 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 745
TABLE 1062 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 745
TABLE 1063 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 746
TABLE 1064 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER,
2024- 2031 (USD BILLION) 746
TABLE 1065 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 746
TABLE 1066 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 747
TABLE 1067 AUSTRALIA: KEY MACROINDICATORS 748
TABLE 1068 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 748
TABLE 1069 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 749
TABLE 1070 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 749
TABLE 1071 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 749
TABLE 1072 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 750
TABLE 1073 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 750
TABLE 1074 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 750
TABLE 1075 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 751
TABLE 1076 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 751
TABLE 1077 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 751
TABLE 1078 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 752
TABLE 1079 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 752
TABLE 1080 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 752
TABLE 1081 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 753
TABLE 1082 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 753
TABLE 1083 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 753
TABLE 1084 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 754
TABLE 1085 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 754
TABLE 1086 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 754
TABLE 1087 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 755
TABLE 1088 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 755
TABLE 1089 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 755
TABLE 1090 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 756
TABLE 1091 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 756
TABLE 1092 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 756
TABLE 1093 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 757
TABLE 1094 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 757
TABLE 1095 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 757
TABLE 1096 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 758
TABLE 1097 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 758
TABLE 1098 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 758
TABLE 1099 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 759
TABLE 1100 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 759
TABLE 1101 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 759
TABLE 1102 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 760
TABLE 1103 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 760
TABLE 1104 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 760
TABLE 1105 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 761
TABLE 1106 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 761
TABLE 1107 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 761
TABLE 1108 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 762
TABLE 1109 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 762
TABLE 1110 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024-2031 (USD BILLION) 762
TABLE 1111 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 763
TABLE 1112 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 763
TABLE 1113 SOUTH KOREA: KEY MACROINDICATORS 764
TABLE 1114 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 764
TABLE 1115 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 765
TABLE 1116 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 765
TABLE 1117 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 765
TABLE 1118 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 766
TABLE 1119 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 766
TABLE 1120 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 766
TABLE 1121 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 767
TABLE 1122 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 767
TABLE 1123 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 767
TABLE 1124 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 768
TABLE 1125 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 768
TABLE 1126 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 768
TABLE 1127 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 769
TABLE 1128 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 769
TABLE 1129 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 769
TABLE 1130 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 770
TABLE 1131 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 770
TABLE 1132 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 770
TABLE 1133 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 771
TABLE 1134 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 771
TABLE 1135 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 771
TABLE 1136 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 772
TABLE 1137 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 772
TABLE 1138 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 772
TABLE 1139 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 773
TABLE 1140 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER,
2024- 2031 (USD BILLION) 773
TABLE 1141 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 773
TABLE 1142 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 774
TABLE 1143 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 774
TABLE 1144 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 774
TABLE 1145 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 775
TABLE 1146 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 775
TABLE 1147 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 775
TABLE 1148 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 776
TABLE 1149 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 776
TABLE 1150 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 776
TABLE 1151 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 777
TABLE 1152 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 777
TABLE 1153 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 777
TABLE 1154 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 778
TABLE 1155 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 778
TABLE 1156 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER,
2024-2031 (USD BILLION) 778
TABLE 1157 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 779
TABLE 1158 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 779
TABLE 1159 NEW ZEALAND: KEY MACROINDICATORS 780
TABLE 1160 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 780
TABLE 1161 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 781
TABLE 1162 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 781
TABLE 1163 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 781
TABLE 1164 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 782
TABLE 1165 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 782
TABLE 1166 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 782
TABLE 1167 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 783
TABLE 1168 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 783
TABLE 1169 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 783
TABLE 1170 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 784
TABLE 1171 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 784
TABLE 1172 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 784
TABLE 1173 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 785
TABLE 1174 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 785
TABLE 1175 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 785
TABLE 1176 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 786
TABLE 1177 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 786
TABLE 1178 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 786
TABLE 1179 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 787
TABLE 1180 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 787
TABLE 1181 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 787
TABLE 1182 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 788
TABLE 1183 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 788
TABLE 1184 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 788
TABLE 1185 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 789
TABLE 1186 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 789
TABLE 1187 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 789
TABLE 1188 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 790
TABLE 1189 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 790
TABLE 1190 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 790
TABLE 1191 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 791
TABLE 1192 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 791
TABLE 1193 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 791
TABLE 1194 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 792
TABLE 1195 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 792
TABLE 1196 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 792
TABLE 1197 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 793
TABLE 1198 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 793
TABLE 1199 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 793

TABLE 1200 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 794
TABLE 1201 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 794
TABLE 1202 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER,
2024- 2031 (USD BILLION) 794
TABLE 1203 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 795
TABLE 1204 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 795
TABLE 1205 THAILAND: KEY MACROINDICATORS 796
TABLE 1206 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 796
TABLE 1207 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 797
TABLE 1208 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 797
TABLE 1209 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 797
TABLE 1210 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 798
TABLE 1211 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 798
TABLE 1212 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 798
TABLE 1213 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 799
TABLE 1214 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 799
TABLE 1215 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 799
TABLE 1216 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 800
TABLE 1217 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 800
TABLE 1218 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 800
TABLE 1219 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 801
TABLE 1220 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 801
TABLE 1221 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 801
TABLE 1222 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 802
TABLE 1223 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 802
TABLE 1224 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 802
TABLE 1225 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 803
TABLE 1226 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 803
TABLE 1227 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 803
TABLE 1228 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 804
TABLE 1229 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 804
TABLE 1230 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 804
TABLE 1231 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 805
TABLE 1232 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 805
TABLE 1233 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 805
TABLE 1234 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 806
TABLE 1235 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 806
TABLE 1236 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 806
TABLE 1237 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 807
TABLE 1238 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024- 2031 (USD BILLION) 807
TABLE 1239 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 807
TABLE 1240 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 808
TABLE 1241 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 808
TABLE 1242 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 808
TABLE 1243 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 809
TABLE 1244 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 809
TABLE 1245 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 809
TABLE 1246 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 810
TABLE 1247 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 810
TABLE 1248 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 810
TABLE 1249 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 811
TABLE 1250 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 811
TABLE 1251 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 813
TABLE 1252 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 813
TABLE 1253 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 813
TABLE 1254 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 814
TABLE 1255 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 814
TABLE 1256 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 814
TABLE 1257 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 815
TABLE 1258 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 815
TABLE 1259 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 815
TABLE 1260 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 816
TABLE 1261 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 816
TABLE 1262 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 816
TABLE 1263 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 817
TABLE 1264 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 817
TABLE 1265 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 817
TABLE 1266 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 818
TABLE 1267 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 818
TABLE 1268 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 818
TABLE 1269 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 819
TABLE 1270 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 819
TABLE 1271 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 819
TABLE 1272 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 820
TABLE 1273 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024-2031 (USD BILLION) 820
TABLE 1274 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 820
TABLE 1275 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 821
TABLE 1276 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 821
TABLE 1277 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024-2031 (USD BILLION) 821
TABLE 1278 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 822
TABLE 1279 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 822
TABLE 1280 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 822
TABLE 1281 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 823
TABLE 1282 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 823
TABLE 1283 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 823
TABLE 1284 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 824
TABLE 1285 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 824
TABLE 1286 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 825
TABLE 1287 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 825
TABLE 1288 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 825
TABLE 1289 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 826
TABLE 1290 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 826
TABLE 1291 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 826
TABLE 1292 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 827
TABLE 1293 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 827
TABLE 1294 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024- 2031 (USD BILLION) 827
TABLE 1295 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 828
TABLE 1296 LATIN AMERICA: VOLUME ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031 (TEN THOUSAND UNITS) 829
TABLE 1297 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024- 2031 (USD BILLION) 830
TABLE 1298 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 830
TABLE 1299 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 831
TABLE 1300 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 831
TABLE 1301 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 831
TABLE 1302 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 832
TABLE 1303 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 832
TABLE 1304 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 832
TABLE 1305 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 833
TABLE 1306 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 833
TABLE 1307 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 833
TABLE 1308 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 834
TABLE 1309 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 834
TABLE 1310 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 834
TABLE 1311 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 835
TABLE 1312 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 835
TABLE 1313 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 835
TABLE 1314 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 836
TABLE 1315 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 836
TABLE 1316 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 836
TABLE 1317 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 837
TABLE 1318 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 837
TABLE 1319 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 837
TABLE 1320 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024-2031 (USD BILLION) 838
TABLE 1321 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 838
TABLE 1322 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 838
TABLE 1323 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 839
TABLE 1324 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024-2031 (USD BILLION) 839
TABLE 1325 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 839
TABLE 1326 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 840
TABLE 1327 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 840
TABLE 1328 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 840
TABLE 1329 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 841
TABLE 1330 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 841
TABLE 1331 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 841
TABLE 1332 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 842
TABLE 1333 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 842
TABLE 1334 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 842
TABLE 1335 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 843
TABLE 1336 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 843
TABLE 1337 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 843
TABLE 1338 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 844
TABLE 1339 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 844
TABLE 1340 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 844
TABLE 1341 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 845
TABLE 1342 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 845
TABLE 1343 BRAZIL: KEY MACROINDICATORS 846
TABLE 1344 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 847
TABLE 1345 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 847
TABLE 1346 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 847
TABLE 1347 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 848
TABLE 1348 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 848
TABLE 1349 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 848
TABLE 1350 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 849
TABLE 1351 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 849
TABLE 1352 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 849
TABLE 1353 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 850
TABLE 1354 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 850
TABLE 1355 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 850
TABLE 1356 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 851
TABLE 1357 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 851
TABLE 1358 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 851
TABLE 1359 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 852
TABLE 1360 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 852
TABLE 1361 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 852
TABLE 1362 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024- 2031 (USD BILLION) 853
TABLE 1363 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024- 2031 (USD BILLION) 853
TABLE 1364 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 853
TABLE 1365 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 854
TABLE 1366 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 854
TABLE 1367 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 854
TABLE 1368 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 855
TABLE 1369 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 855
TABLE 1370 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 855
TABLE 1371 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 856
TABLE 1372 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 856
TABLE 1373 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 856
TABLE 1374 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 857
TABLE 1375 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 857
TABLE 1376 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024- 2031 (USD BILLION) 857
TABLE 1377 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 858
TABLE 1378 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 858
TABLE 1379 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 859
TABLE 1380 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 859
TABLE 1381 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 859
TABLE 1382 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 860
TABLE 1383 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 860
TABLE 1384 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 860
TABLE 1385 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 861
TABLE 1386 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 861
TABLE 1387 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 861
TABLE 1388 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 862
TABLE 1389 MEXICO: KEY MACROINDICATORS 863
TABLE 1390 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 863
TABLE 1391 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 863
TABLE 1392 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 864
TABLE 1393 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 864
TABLE 1394 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 864
TABLE 1395 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 865
TABLE 1396 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 865
TABLE 1397 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 865
TABLE 1398 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 866
TABLE 1399 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 866
TABLE 1400 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 866
TABLE 1401 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 867
TABLE 1402 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 867
TABLE 1403 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 867
TABLE 1404 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 868
TABLE 1405 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 868
TABLE 1406 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 868
TABLE 1407 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 869
TABLE 1408 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 869
TABLE 1409 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 869
TABLE 1410 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 870
TABLE 1411 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 870
TABLE 1412 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 870
TABLE 1413 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 871
TABLE 1414 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 871
TABLE 1415 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 871
TABLE 1416 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 872
TABLE 1417 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024–2031 (USD BILLION) 872
TABLE 1418 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024–2031 (USD BILLION) 872
TABLE 1419 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024–2031 (USD BILLION) 873
TABLE 1420 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024–2031 (USD BILLION) 873
TABLE 1421 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 873
TABLE 1422 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024–2031 (USD BILLION) 874
TABLE 1423 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 874
TABLE 1424 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 874
TABLE 1425 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 875
TABLE 1426 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 875
TABLE 1427 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 875
TABLE 1428 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 876
TABLE 1429 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 876
TABLE 1430 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 876
TABLE 1431 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 877
TABLE 1432 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024–2031 (USD BILLION) 877
TABLE 1433 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024–2031 (USD BILLION) 877
TABLE 1434 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024–2031 (USD BILLION) 878
TABLE 1435 ARGENTINA: KEY MACROINDICATORS 878
TABLE 1436 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD BILLION) 879
TABLE 1437 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 879
TABLE 1438 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024–2031 (USD BILLION) 879
TABLE 1439 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024–2031 (USD BILLION) 880
TABLE 1440 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024–2031 (USD BILLION) 880
TABLE 1441 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024–2031 (USD BILLION) 880
TABLE 1442 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024–2031 (USD BILLION) 881
TABLE 1443 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024–2031 (USD BILLION) 881
TABLE 1444 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024–2031 (USD BILLION) 881
TABLE 1445 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024–2031 (USD BILLION) 882
TABLE 1446 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 882
TABLE 1447 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 882
TABLE 1448 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 883
TABLE 1449 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024–2031 (USD BILLION) 883
TABLE 1450 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 883
TABLE 1451 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 884
TABLE 1452 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 884
TABLE 1453 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 884
TABLE 1454 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024–2031 (USD BILLION) 885
TABLE 1455 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024–2031 (USD BILLION) 885
TABLE 1456 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024–2031 (USD BILLION) 885
TABLE 1457 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024–2031 (USD BILLION) 886
TABLE 1458 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024–2031 (USD BILLION) 886
TABLE 1459 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024–2031 (USD BILLION) 886
TABLE 1460 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024–2031 (USD BILLION) 887
TABLE 1461 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024–2031 (USD BILLION) 887
TABLE 1462 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024–2031 (USD BILLION) 887
TABLE 1463 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024–2031 (USD BILLION) 888
TABLE 1464 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024–2031 (USD BILLION) 888
TABLE 1465 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024–2031 (USD BILLION) 888
TABLE 1466 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024–2031 (USD BILLION) 889
TABLE 1467 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 889
TABLE 1468 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024–2031 (USD BILLION) 889
TABLE 1469 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 890
TABLE 1470 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 890
TABLE 1471 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 890

TABLE 1472 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 891
TABLE 1473 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 891
TABLE 1474 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 891
TABLE 1475 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 892
TABLE 1476 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 892
TABLE 1477 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 892
TABLE 1478 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024–2031 (USD BILLION) 893
TABLE 1479 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024–2031 (USD BILLION) 893
TABLE 1480 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024–2031 (USD BILLION) 893
TABLE 1481 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD BILLION) 894
TABLE 1482 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 895
TABLE 1483 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024–2031 (USD BILLION) 895
TABLE 1484 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024–2031 (USD BILLION) 895
TABLE 1485 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024–2031 (USD BILLION) 896
TABLE 1486 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024–2031 (USD BILLION) 896
TABLE 1487 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024–2031 (USD BILLION) 896
TABLE 1488 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024–2031 (USD BILLION) 897
TABLE 1489 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024–2031 (USD BILLION) 897
TABLE 1490 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024–2031 (USD BILLION) 897
TABLE 1491 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 898
TABLE 1492 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 898
TABLE 1493 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 898
TABLE 1494 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024–2031 (USD BILLION) 899
TABLE 1495 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 899
TABLE 1496 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 899
TABLE 1497 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 900
TABLE 1498 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 900
TABLE 1499 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024–2031 (USD BILLION) 900
TABLE 1500 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024–2031 (USD BILLION) 901
TABLE 1501 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024–2031 (USD BILLION) 901
TABLE 1502 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024–2031 (USD BILLION) 901
TABLE 1503 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024–2031 (USD BILLION) 902
TABLE 1504 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024–2031 (USD BILLION) 902
TABLE 1505 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024–2031 (USD BILLION) 902
TABLE 1506 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024–2031 (USD BILLION) 903
TABLE 1507 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024–2031 (USD BILLION) 903
TABLE 1508 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024–2031 (USD BILLION) 903
TABLE 1509 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024–2031 (USD BILLION) 904
TABLE 1510 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024–2031 (USD BILLION) 904
TABLE 1511 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024–2031 (USD BILLION) 904
TABLE 1512 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 905
TABLE 1513 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024–2031 (USD BILLION) 905
TABLE 1514 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 905
TABLE 1515 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 906
TABLE 1516 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 906
TABLE 1517 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 906
TABLE 1518 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 907
TABLE 1519 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 907
TABLE 1520 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 907
TABLE 1521 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 908
TABLE 1522 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 908
TABLE 1523 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024–2031 (USD BILLION) 908
TABLE 1524 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET,
BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER,
2024–2031 (USD BILLION) 909
TABLE 1525 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024–2031 (USD BILLION) 909
TABLE 1526 MIDDLE EAST & AFRICA: VOLUME ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024–2031 (TEN THOUSAND UNITS) 911
TABLE 1527 MIDDLE EAST & AFRICA MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 911
TABLE 1528 MEA MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PRODUCT, 2024–2031 (USD BILLION) 912
TABLE 1529 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 912
TABLE 1530 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024–2031 (USD BILLION) 913
TABLE 1531 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024–2031 (USD BILLION) 913
TABLE 1532 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024–2031 (USD BILLION) 913
TABLE 1533 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024–2031 (USD BILLION) 914
TABLE 1534 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024–2031 (USD BILLION) 914
TABLE 1535 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024–2031 (USD BILLION) 914
TABLE 1536 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024–2031 (USD BILLION) 915
TABLE 1537 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024–2031 (USD BILLION) 915
TABLE 1538 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 915
TABLE 1539 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 916
TABLE 1540 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 916
TABLE 1541 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024–2031 (USD BILLION) 916
TABLE 1542 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 917
TABLE 1543 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 917
TABLE 1544 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 917
TABLE 1545 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 918
TABLE 1546 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024–2031 (USD BILLION) 918
TABLE 1547 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024–2031 (USD BILLION) 918
TABLE 1548 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024–2031 (USD BILLION) 919
TABLE 1549 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024–2031 (USD BILLION) 919
TABLE 1550 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024–2031 (USD BILLION) 919
TABLE 1551 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024–2031 (USD BILLION) 920
TABLE 1552 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024–2031 (USD BILLION) 920
TABLE 1553 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024–2031 (USD BILLION) 920
TABLE 1554 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024–2031 (USD BILLION) 921
TABLE 1555 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024–2031 (USD BILLION) 921
TABLE 1556 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024–2031 (USD BILLION) 921
TABLE 1557 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024–2031 (USD BILLION) 922
TABLE 1558 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024–2031 (USD BILLION) 922
TABLE 1559 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 922
TABLE 1560 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024–2031 (USD BILLION) 923
TABLE 1561 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 923
TABLE 1562 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 923
TABLE 1563 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 924
TABLE 1564 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 924
TABLE 1565 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 924
TABLE 1566 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 925
TABLE 1567 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 925
TABLE 1568 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 925
TABLE 1569 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 926
TABLE 1570 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024–2031 (USD BILLION) 926
TABLE 1571 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024–2031 (USD BILLION) 926
TABLE 1572 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024–2031 (USD BILLION) 927
TABLE 1573 GCC GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 928
TABLE 1574 GCC GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD BILLION) 928
TABLE 1575 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 928
TABLE 1576 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024–2031 (USD BILLION) 929
TABLE 1577 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024–2031 (USD BILLION) 929
TABLE 1578 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024–2031 (USD BILLION) 929
TABLE 1579 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024–2031 (USD BILLION) 930
TABLE 1580 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024–2031 (USD BILLION) 930
TABLE 1581 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024–2031 (USD BILLION) 930
TABLE 1582 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024–2031 (USD BILLION) 931
TABLE 1583 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024–2031 (USD BILLION) 931
TABLE 1584 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 931
TABLE 1585 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 932
TABLE 1586 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 932
TABLE 1587 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024–2031 (USD BILLION) 932
TABLE 1588 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 933
TABLE 1589 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 933
TABLE 1590 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 933
TABLE 1591 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 934
TABLE 1592 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024–2031 (USD BILLION) 934
TABLE 1593 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024–2031 (USD BILLION) 934
TABLE 1594 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024–2031 (USD BILLION) 935
TABLE 1595 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024–2031 (USD BILLION) 935
TABLE 1596 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024–2031 (USD BILLION) 935
TABLE 1597 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024–2031 (USD BILLION) 936
TABLE 1598 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024–2031 (USD BILLION) 936
TABLE 1599 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024–2031 (USD BILLION) 936
TABLE 1600 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024–2031 (USD BILLION) 937
TABLE 1601 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024–2031 (USD BILLION) 937
TABLE 1602 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024–2031 (USD BILLION) 937
TABLE 1603 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024–2031 (USD BILLION) 938
TABLE 1604 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024–2031 (USD BILLION) 938
TABLE 1605 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 938
TABLE 1606 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024–2031 (USD BILLION) 939
TABLE 1607 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 939
TABLE 1608 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 939
TABLE 1609 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 940
TABLE 1610 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 940
TABLE 1611 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 940
TABLE 1612 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 941
TABLE 1613 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 941
TABLE 1614 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 941
TABLE 1615 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 942
TABLE 1616 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024–2031 (USD BILLION) 942
TABLE 1617 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER,
2024–2031 (USD BILLION) 942
TABLE 1618 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024–2031 (USD BILLION) 943
TABLE 1619 KSA: KEY MACROINDICATORS 943
TABLE 1620 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD BILLION) 944
TABLE 1621 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 944
TABLE 1622 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024–2031 (USD BILLION) 944
TABLE 1623 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024–2031 (USD BILLION) 945
TABLE 1624 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024–2031 (USD BILLION) 945
TABLE 1625 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024–2031 (USD BILLION) 945
TABLE 1626 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024–2031 (USD BILLION) 946
TABLE 1627 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024–2031 (USD BILLION) 946
TABLE 1628 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING,
2024–2031 (USD BILLION) 946
TABLE 1629 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024–2031 (USD BILLION) 947
TABLE 1630 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 947
TABLE 1631 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 947
TABLE 1632 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 948
TABLE 1633 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024–2031 (USD BILLION) 948
TABLE 1634 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 948
TABLE 1635 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 949
TABLE 1636 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 949
TABLE 1637 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 949
TABLE 1638 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024–2031 (USD BILLION) 950
TABLE 1639 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024–2031 (USD BILLION) 950
TABLE 1640 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024–2031 (USD BILLION) 950
TABLE 1641 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024–2031 (USD BILLION) 951
TABLE 1642 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024–2031 (USD BILLION) 951
TABLE 1643 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024–2031 (USD BILLION) 951
TABLE 1644 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024–2031 (USD BILLION) 952
TABLE 1645 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024–2031 (USD BILLION) 952
TABLE 1646 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024–2031 (USD BILLION) 952
TABLE 1647 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024–2031 (USD BILLION) 953
TABLE 1648 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024–2031 (USD BILLION) 953
TABLE 1649 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024–2031 (USD BILLION) 953
TABLE 1650 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES,
2024–2031 (USD BILLION) 954
TABLE 1651 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 954
TABLE 1652 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024–2031 (USD BILLION) 954
TABLE 1653 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 955
TABLE 1654 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 955
TABLE 1655 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 956
TABLE 1656 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 956
TABLE 1657 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 956
TABLE 1658 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 957
TABLE 1659 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 957
TABLE 1660 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 957
TABLE 1661 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 958
TABLE 1662 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024–2031 (USD BILLION) 958
TABLE 1663 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024–2031 (USD BILLION) 958
TABLE 1664 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER,
2024–2031 (USD BILLION) 959
TABLE 1665 UAE: KEY MACROINDICATORS 960
TABLE 1666 UAE UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD BILLION) 960
TABLE 1667 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 960
TABLE 1668 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024–2031 (USD BILLION) 961
TABLE 1669 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024–2031 (USD BILLION) 961
TABLE 1670 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024–2031 (USD BILLION) 961
TABLE 1671 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024–2031 (USD BILLION) 962
TABLE 1672 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024–2031 (USD BILLION) 962
TABLE 1673 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024–2031 (USD BILLION) 962
TABLE 1674 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024–2031 (USD BILLION) 963
TABLE 1675 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024–2031 (USD BILLION) 963
TABLE 1676 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 963
TABLE 1677 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 964
TABLE 1678 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 964
TABLE 1679 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024–2031 (USD BILLION) 964
TABLE 1680 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 965
TABLE 1681 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 965
TABLE 1682 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 965
TABLE 1683 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 966
TABLE 1684 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024–2031 (USD BILLION) 966
TABLE 1685 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024–2031 (USD BILLION) 966
TABLE 1686 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024–2031 (USD BILLION) 967
TABLE 1687 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024–2031 (USD BILLION) 967
TABLE 1688 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024–2031 (USD BILLION) 967
TABLE 1689 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024–2031 (USD BILLION) 968
TABLE 1690 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024–2031 (USD BILLION) 968
TABLE 1691 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024–2031 (USD BILLION) 968
TABLE 1692 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024–2031 (USD BILLION) 969
TABLE 1693 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024–2031 (USD BILLION) 969
TABLE 1694 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024–2031 (USD BILLION) 969
TABLE 1695 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024–2031 (USD BILLION) 970
TABLE 1696 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024–2031 (USD BILLION) 970
TABLE 1697 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 970
TABLE 1698 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024–2031 (USD BILLION) 971
TABLE 1699 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 971
TABLE 1700 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 971
TABLE 1701 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 972
TABLE 1702 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 972
TABLE 1703 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 972
TABLE 1704 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 973
TABLE 1705 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 973
TABLE 1706 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 973
TABLE 1707 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 974
TABLE 1708 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024–2031 (USD BILLION) 974
TABLE 1709 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER,
2024–2031 (USD BILLION) 974
TABLE 1710 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024–2031 (USD BILLION) 975
TABLE 1711 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD BILLION) 976
TABLE 1712 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 976
TABLE 1713 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024–2031 (USD BILLION) 976
TABLE 1714 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024–2031 (USD BILLION) 977
TABLE 1715 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024–2031 (USD BILLION) 977
TABLE 1716 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024–2031 (USD BILLION) 977
TABLE 1717 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024–2031 (USD BILLION) 978
TABLE 1718 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024–2031 (USD BILLION) 978
TABLE 1719 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING,
2024–2031 (USD BILLION) 978

TABLE 1720 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024–2031 (USD BILLION) 979
TABLE 1721 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 979
TABLE 1722 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 979
TABLE 1723 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 980
TABLE 1724 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024–2031 (USD BILLION) 980
TABLE 1725 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 980
TABLE 1726 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 981
TABLE 1727 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 981
TABLE 1728 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 981
TABLE 1729 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024–2031 (USD BILLION) 982
TABLE 1730 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024–2031 (USD BILLION) 982
TABLE 1731 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024–2031 (USD BILLION) 982
TABLE 1732 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024–2031 (USD BILLION) 983
TABLE 1733 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024–2031 (USD BILLION) 983
TABLE 1734 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024–2031 (USD BILLION) 983
TABLE 1735 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024–2031 (USD BILLION) 984
TABLE 1736 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024–2031 (USD BILLION) 984
TABLE 1737 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024–2031 (USD BILLION) 984
TABLE 1738 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024–2031 (USD BILLION) 985
TABLE 1739 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024–2031 (USD BILLION) 985
TABLE 1740 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024–2031 (USD BILLION) 985
TABLE 1741 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024–2031 (USD BILLION) 986
TABLE 1742 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 986
TABLE 1743 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024–2031 (USD BILLION) 986
TABLE 1744 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 987
TABLE 1745 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 987
TABLE 1746 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 988
TABLE 1747 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 988
TABLE 1748 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 988
TABLE 1749 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 989
TABLE 1750 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 989
TABLE 1751 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 989
TABLE 1752 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 990
TABLE 1753 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024–2031 (USD BILLION) 990
TABLE 1754 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET,
BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER,
2024–2031 (USD BILLION) 990
TABLE 1755 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024–2031 (USD BILLION) 991
TABLE 1756 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD BILLION) 992
TABLE 1757 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 992
TABLE 1758 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024–2031 (USD BILLION) 992
TABLE 1759 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 993
TABLE 1760 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 993
TABLE 1761 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 993
TABLE 1762 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 994
TABLE 1763 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 994
TABLE 1764 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING,
2024-2031 (USD BILLION) 995
TABLE 1765 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 995
TABLE 1766 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 995
TABLE 1767 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 996
TABLE 1768 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 996
TABLE 1769 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 996
TABLE 1770 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 997
TABLE 1771 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 997
TABLE 1772 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 997
TABLE 1773 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 998
TABLE 1774 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 998
TABLE 1775 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 998
TABLE 1776 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 999
TABLE 1777 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 999
TABLE 1778 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024-2031 (USD BILLION) 999
TABLE 1779 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 1000
TABLE 1780 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 1000
TABLE 1781 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 1000
TABLE 1782 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024-2031 (USD BILLION) 1001
TABLE 1783 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 1001
TABLE 1784 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 1001
TABLE 1785 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 1002
TABLE 1786 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET,
BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES,
2024-2031 (USD BILLION) 1002
TABLE 1787 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 1002
TABLE 1788 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 1003
TABLE 1789 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 1003
TABLE 1790 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 1004
TABLE 1791 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 1004
TABLE 1792 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 1005
TABLE 1793 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 1005
TABLE 1794 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 1005
TABLE 1795 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 1006
TABLE 1796 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 1006
TABLE 1797 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 1006
TABLE 1798 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024-2031 (USD BILLION) 1007
TABLE 1799 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET,
BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER,
2024-2031 (USD BILLION) 1007
TABLE 1800 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 1007
TABLE 1801 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN
PHARMACEUTICAL DRUG DELIVERY MARKET 1008
TABLE 1802 INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS: DEGREE OF COMPETITION 1012
TABLE 1803 GLOBAL INJECTABLE DRUG DELIVERY MANUFACTURERS: DEGREE OF COMPETITION 1014
TABLE 1804 US INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS: DEGREE OF COMPETITION 1017
TABLE 1805 EUROPE INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS: DEGREE OF COMPETITION 1018
TABLE 1806 GLOBAL ORAL DRUG DELIVERY MANUFACTURERS: DEGREE OF COMPETITION 1019
TABLE 1807 US ORAL DRUG DELIVERY FORMULATION MANUFACTURERS: DEGREE OF COMPETITION 1020
TABLE 1808 EUROPE ORAL DRUG DELIVERY MANUFACTURERS: DEGREE OF COMPETITION 1021
TABLE 1809 GLOBAL TOPICAL DRUG DELIVERY MANUFACTURERS: DEGREE OF COMPETITION 1022
TABLE 1810 US TOPICAL DRUG DELIVERY MANUFACTURERS: DEGREE OF COMPETITION 1023
TABLE 1811 EUROPE TOPICAL DRUG DELIVERY MANUFACTURERS: DEGREE OF COMPETITION 1024
TABLE 1812 PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS: REGION FOOTPRINT 1030
TABLE 1813 PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS: PRODUCT TYPE FOOTPRINT 1030
TABLE 1814 PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS: USABILITY FOOTPRINT 1031
TABLE 1815 PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS: REGION FOOTPRINT 1034
TABLE 1816 PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS: ROUTE OF ADMINISTRATION FOOTPRINT 1035
TABLE 1817 PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS: APPLICATION FOOTPRINT 1036
TABLE 1818 PHARMACEUTICAL DRUG DELIVERY MARKET: DETAILED LIST OF KEY INJECTABLE DRUG DELIVERY FORMULATION STARTUPS/SME PLAYERS 1039
TABLE 1819 PHARMACEUTICAL DRUG DELIVERY MARKET: COMPETITIVE BENCHMARKING OF PHARMACEUTICAL DRUG DELIVERY FORMULATION STARTUPS/SMES 1039
TABLE 1820 PHARMACEUTICAL DRUG DELIVERY MARKET: PRODUCT APPROVALS AND LAUNCHES, JANUARY 2022- APRIL 2026 1040
TABLE 1821 PHARMACEUTICAL DRUG DELIVERY MARKET: DEALS, JANUARY 2022- APRIL 2026 1041
TABLE 1822 PHARMACEUTICAL DRUG DELIVERY MARKET: EXPANSIONS,
JANUARY 2022–APRIL 2026 1042
TABLE 1823 PHARMACEUTICAL DRUG DELIVERY MARKET: OTHER DEVELOPMENTS, JANUARY 2022–APRIL 2026 1043
TABLE 1824 JOHNSON & JOHNSON: COMPANY OVERVIEW 1044
TABLE 1825 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED 1045
TABLE 1826 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT APPROVALS, JANUARY 2022−APRIL 2026 1047
TABLE 1827 JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2022−APRIL 2026 1054
TABLE 1828 JOHNSON & JOHNSON: EXPANSIONS, JANUARY 2022−APRIL 2026 1056
TABLE 1829 JOHNSON & JOHNSON: OTHERS, JANUARY 2022−APRIL 2026 1056
TABLE 1830 NOVARTIS AG: COMPANY OVERVIEW 1058
TABLE 1831 NOVARTIS AG: PRODUCTS OFFERED 1059
TABLE 1832 NOVARTIS AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1062
TABLE 1833 NOVARTIS AG: DEALS, JANUARY 2022–APRIL 2026 1064
TABLE 1834 NOVARTIS AG: EXPANSIONS, JANUARY 2022–APRIL 2026 1066
TABLE 1835 NOVARTIS: OTHERS, JANUARY 2022−APRIL 2026 1067
TABLE 1836 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 1069
TABLE 1837 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 1070
TABLE 1838 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1072
TABLE 1839 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2022−APRIL 2026 1077
TABLE 1840 F. HOFFMANN-LA ROCHE LTD: EXPANSIONS, JANUARY 2022–APRIL 2026 1078
TABLE 1841 F. HOFFMANN-LA ROCHE LTD: OTHERS, JANUARY 2022−APRIL 2026 1079
TABLE 1842 PFIZER INC.: COMPANY OVERVIEW 1080
TABLE 1843 PFIZER INC.: PRODUCTS OFFERED 1081
TABLE 1844 PFIZER INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1087
TABLE 1845 PFIZER INC.: DEALS, JANUARY 2022–APRIL 2026 1090
TABLE 1846 ELI LILLY AND COMPANY: COMPANY OVERVIEW 1093
TABLE 1847 ELI LILLY AND COMPANY: PRODUCTS OFFERED 1094
TABLE 1848 ELI LILLY AND COMPANY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1095
TABLE 1849 ELI LILLY AND COMPANY: DEALS, JANUARY 2022−APRIL 2026 1098
TABLE 1850 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2022–APRIL 2026 1100
TABLE 1851 GSK PLC.: COMPANY OVERVIEW 1103
TABLE 1852 GSK PLC.: PRODUCTS OFFERED 1104
TABLE 1853 GSK PLC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1109
TABLE 1854 GSK PLC.: DEALS, JANUARY 2022–APRIL 2026 1112
TABLE 1855 GSK PLC.: OTHER DEVELOPMENTS, JANUARY 2022−APRIL 2026 1115
TABLE 1856 ABBVIE INC.: COMPANY OVERVIEW 1116
TABLE 1857 ABBVIE INC.: PRODUCTS OFFERED 1117
TABLE 1858 ABBVIE INC.: PRODUCT APPROVALS, JANUARY 2022— APRIL 2026 1121
TABLE 1859 ABBVIE INC.: DEALS, JANUARY 2022— APRIL 2026 1123
TABLE 1860 ABBVIE INC.: EXPANSION, JANUARY 2022- APRIL 2026 1126
TABLE 1861 ABBVIE, INC: OTHER DEVELOPMENTS, JANUARY 2022-APRIL 2026 1127
TABLE 1862 MERCK & CO., INC.: COMPANY OVERVIEW 1128
TABLE 1863 MERCK & CO., INC.: PRODUCTS OFFERED 1129
TABLE 1864 MERCK & CO., INC.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–APRIL 2026 1132
TABLE 1865 MERCK & CO., INC.: DEALS, JANUARY 2022–APRIL 2026 1137
TABLE 1866 MERCK & CO., INC.: EXPANSIONS, JANUARY 2022–APRIL 2026 1140
TABLE 1867 MERCK & CO., INC: OTHER DEVELOPMENTS, JANUARY 2022−APRIL 2026 1140
TABLE 1868 BAUSCH HEALTH COMPANIES INC.: COMPANY OVERVIEW 1141
TABLE 1869 BAUSCH HEALTH COMPANIES INC.: PRODUCTS OFFERED 1142
TABLE 1870 BAUSCH HEALTH COMPANIES INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1145
TABLE 1871 BAUSCH HEALTH COMPANIES INC.: DEALS, JANUARY 2022–APRIL 2026 1146
TABLE 1872 BAYER AG: COMPANY OVERVIEW 1147
TABLE 1873 BAYER AG: PRODUCTS OFFERED 1148
TABLE 1874 BAYER AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1150
TABLE 1875 BAYER AG: DEALS, JANUARY 2022–APRIL 2026 1155
TABLE 1876 BAYER AG: EXPANSIONS, JANUARY 2022–APRIL 2026 1157
TABLE 1877 BAYER AG: OTHER DEVELOPMENTS, JANUARY 2022−APRIL 2026 1158
TABLE 1878 AMGEN INC.: COMPANY OVERVIEW 1159
TABLE 1879 AMGEN INC.: PRODUCTS OFFERED 1160
TABLE 1880 AMGEN INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1161
TABLE 1881 AMGEN INC.: DEALS, JANUARY 2022–APRIL 2026 1163
TABLE 1882 AMGEN INC.: EXPANSIONS, JANUARY 2022–APRIL 2026 1164
TABLE 1883 ASTRAZENECA: COMPANY OVERVIEW 1166
TABLE 1884 ASTRAZENECA: PRODUCTS OFFERED 1167
TABLE 1885 ASTRAZENECA: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1170
TABLE 1886 ASTRAZENECA: DEALS, JANUARY 2022–APRIL 2026 1177
TABLE 1887 ASTRAZENECA: EXPANSIONS, JANUARY 2022–APRIL 2026 1178
TABLE 1888 ASTRAZENECA: OTHER DEVELOPMENTS, JANUARY 2022−APRIL 2026 1179
TABLE 1889 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 1180
TABLE 1890 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED 1181
TABLE 1891 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1182
TABLE 1892 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS,
JANUARY 2022−APRIL 2026 1183
TABLE 1893 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS,
JANUARY 2022−APRIL 2026 1186
TABLE 1894 RUSAN PHARMA LTD.: COMPANY OVERVIEW 1199
TABLE 1895 CMP PHARMA, INC.: COMPANY OVERVIEW 1200
TABLE 1896 XERIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW 1201
TABLE 1897 ADHEXPHARMA: COMPANY OVERVIEW 1202
TABLE 1898 BD: COMPANY OVERVIEW 1203
TABLE 1899 BD: PRODUCTS OFFERED 1204
TABLE 1900 BD: DEALS, JANUARY 2022−APRIL 2026 1207
TABLE 1901 BD: EXPANSIONS, JANUARY 2022–APRIL 2026 1207
TABLE 1902 BD: OTHER DEVELOPMENTS, JANUARY 2022−APRIL 2026 1208
TABLE 1903 CARDINAL HEALTH: COMPANY OVERVIEW 1209
TABLE 1904 CARDINAL HEALTH: PRODUCTS OFFERED 1210
TABLE 1905 CARDINAL HEALTH: EXPANSIONS, JANUARY 2022–APRIL 2026 1211
TABLE 1906 B. BRAUN SE: COMPANY OVERVIEW 1213
TABLE 1907 B. BRAUN SE: PRODUCTS OFFERED 1214
TABLE 1908 TERUMO CORPORATION: COMPANY OVERVIEW (2025) 1216
TABLE 1909 TERUMO CORPORATION: PRODUCTS OFFERED 1217
TABLE 1910 TERUMO CORPORATION: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–APRIL 2026 1218
TABLE 1911 TERUMO CORPORATION: EXPANSIONS, JANUARY 2022–APRIL 2026 1219
TABLE 1912 NIPRO: COMPANY OVERVIEW 1220
TABLE 1913 NIPRO: PRODUCTS OFFERED 1221
TABLE 1914 NIPRO: EXPANSIONS, JANUARY 2022–MARCH 2025 1222
TABLE 1915 STEVANATO GROUP: COMPANY OVERVIEW 1223
TABLE 1916 STEVANATO GROUP: PRODUCTS OFFERED 1224
TABLE 1917 STEVANATO GROUP: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–APRIL 2026 1225
TABLE 1918 STEVANATO: DEALS, JANUARY 2022–APRIL 2026 1225
TABLE 1919 STEVANATO: EXPANSIONS, JANUARY 2022–APRIL 2026 1226
TABLE 1920 STEVANATO GROUP: OTHER DEVELOPMENTS, JANUARY 2022−APRIL 2026 1227
TABLE 1921 GERRESHEIMER AG: COMPANY OVERVIEW 1228
TABLE 1922 GERRESHEIMER AG: PRODUCTS OFFERED 1229
TABLE 1923 GERRESHEIMER AG: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–APRIL 2026 1230
TABLE 1924 GERRESHEIMER AG: DEALS, JANUARY 2022-APRIL 2026 1231
TABLE 1925 GERRESHEIMER AG: EXPANSIONS, JANUARY 2022-APRIL 2026 1232
TABLE 1926 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW 1233
TABLE 1927 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCTS OFFERED 1234
TABLE 1928 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1235
TABLE 1929 WEST PHARMACEUTICAL SERVICES, INC.: DEALS, JANUARY 2022–APRIL 2026 1235
TABLE 1930 WEST PHARMACEUTICAL SERVICES, INC.: EXPANSIONS,
JANUARY 2022–APRIL 2026 1236
TABLE 1931 YPSOMED: BUSINESS OVERVIEW 1237
TABLE 1932 YPSOMED: PRODUCTS OFFERED 1238
TABLE 1933 YPSOMED: PRODUCT LAUNCHES, JANUARY 2022 – APRIL 2026 1239
TABLE 1934 YPSOMED: DEALS, JANUARY 2022−APRIL 2026 1239
TABLE 1935 YPSOMED: EXPANSIONS, JANUARY 2022−APRIL 2026 1241
TABLE 1936 SHL MEDICAL AG: COMPANY OVERVIEW 1242
TABLE 1937 SHL MEDICAL AG: PRODUCTS OFFERED 1242
TABLE 1938 SHL MEDICAL AG: PRODUCT LAUNCHES, JANUARY 2022–APRIL 2026 1243
TABLE 1939 SHL MEDICAL AG: DEALS, JANUARY 2022–APRIL 2026 1244
TABLE 1940 SHL MEDICAL AG: EXPANSIONS, JANUARY 2022–APRIL 2026 1245
TABLE 1941 STUDY ASSUMPTIONS 1262
TABLE 1942 RISK ASSESSMENT ANALYSIS 1263

List Of Figures

FIGURE 1 PHARMACEUTICAL DRUG DELIVERY MARKET SEGMENTATION 106
FIGURE 2 MARKET SCENARIO 111
FIGURE 3 GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, 2024–2031 112
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PHARMACEUTICAL DRUG DELIVERY MARKET, 2020–2025 112
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF PHARMACEUTICAL DRUG DELIVERY MARKET 113
FIGURE 6 HIGH-GROWTH SEGMENTS IN PHARMACEUTICAL DRUG DELIVERY MARKET,
2026–2031 114
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN PHARMACEUTICAL DRUG DELIVERY MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 115
FIGURE 8 INCREASING NEED FOR PHARMACEUTICAL DRUG DELIVERY PRODUCTS TO FUEL MARKET GROWTH 116
FIGURE 9 PHARMACEUTICAL DRUG DELIVERY SEGMENT IN CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN 2025 117
FIGURE 10 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING THE
FORECAST PERIOD 118
FIGURE 11 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 118
FIGURE 12 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 119
FIGURE 13 PHARMACEUTICAL DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 120
FIGURE 14 BIOPHARMACEUTICAL R&D SPENDING (2020–2026) 127
FIGURE 15 PHARMACEUTICAL DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 136
FIGURE 16 PHARMACEUTICAL DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS 142
FIGURE 17 PHARMACEUTICAL DRUG DELIVERY MARKET: ECOSYSTEM ANALYSIS 143
FIGURE 18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 153
FIGURE 19 PHARMACEUTICAL DRUG DELIVERY MARKET: INVESTMENT & FUNDING SCENARIO 154
FIGURE 20 ADDITIONAL LAUNCHES OF GLP-1 DRUGS, 2024–2032 166
FIGURE 21 PHARMACEUTICAL DRUG DELIVERY MARKET: NUMBER OF GRANTED PATENT APPLICATIONS (JANUARY 2015–APRIL 2026) 181
FIGURE 22 TOP APPLICANT COUNTRIES/REGIONS FOR PHARMACEUTICAL DRUG
DELIVERY PATENTS (JANUARY 2015–APRIL 2026) 182
FIGURE 23 AI USE CASES 185
FIGURE 24 KEY STAKEHOLDERS IN BUYING PROCESS FOR PHARMACEUTICAL DRUG
DELIVERY DEVICES 197
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR
PHARMACEUTICAL DRUG DELIVERY FORMULATIONS 198
FIGURE 26 KEY BUYING CRITERIA FOR TOP THREE END USERS 199
FIGURE 27 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT (2025) 465
FIGURE 28 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET SNAPSHOT 468
FIGURE 29 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET SNAPSHOT 681
FIGURE 30 REVENUE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS, 2023−2025 1010
FIGURE 31 REVENUE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS, 2023−2025 1011
FIGURE 32 MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2025 1012
FIGURE 33 RANKING OF KEY INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2025 1013
FIGURE 34 GLOBAL MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1014
FIGURE 35 RANKING OF KEY INJECTABLE DRUG DELIVERY FORMULATION
MANUFACTURERS, 2025 1016
FIGURE 36 US MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1016
FIGURE 37 EUROPE MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1017
FIGURE 38 GLOBAL MARKET SHARE ANALYSIS OF ORAL DRUG DELIVERY
MANUFACTURERS, 2025 1018
FIGURE 39 US MARKET SHARE ANALYSIS OF ORAL DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1019
FIGURE 40 EUROPE MARKET SHARE ANALYSIS OF ORAL DRUG DELIVERY
MANUFACTURERS, 2025 1020
FIGURE 41 GLOBAL MARKET SHARE ANALYSIS OF TOPICAL DRUG DELIVERY MANUFACTURERS, 2025 1021
FIGURE 42 US MARKET SHARE ANALYSIS OF TOPICAL DRUG DELIVERY
MANUFACTURERS, 2025 1022
FIGURE 43 EUROPE MARKET SHARE ANALYSIS OF TOPICAL DRUG DELIVERY MANUFACTURERS, 2025 1023
FIGURE 44 PHARMACEUTICAL DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARISON 1025
FIGURE 45 R&D EXPENDITURE OF KEY PLAYERS IN PHARMACEUTICAL DRUG DELIVERY MARKET, 2023−2025 1026
FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS 1026
FIGURE 47 YEAR-TO-YEAR (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS 1027
FIGURE 48 COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS (2025) 1028
FIGURE 49 PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS: COMPANY FOOTPRINT 1029
FIGURE 50 COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS (2025) 1032
FIGURE 51 PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS:
COMPANY FOOTPRINT 1033
FIGURE 52 PHARMACEUTICAL DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX (PHARMACEUTICAL DRUG DELIVERY FORMULATION STARTUPS/SMES), 2025 1038
FIGURE 53 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2025) 1045
FIGURE 54 NOVARTIS AG: COMPANY SNAPSHOT (2025) 1059
FIGURE 55 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025) 1070
FIGURE 56 PFIZER INC.: COMPANY SNAPSHOT (2025) 1081
FIGURE 57 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2025) 1094
FIGURE 58 GSK PLC.: COMPANY SNAPSHOT (2025) 1104
FIGURE 59 ABBVIE, INC.: COMPANY SNAPSHOT (2025) 1117
FIGURE 60 MERCK & CO., INC.: COMPANY SNAPSHOT (2025) 1129
FIGURE 61 BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2025) 1142
FIGURE 62 BAYER AG: COMPANY SNAPSHOT (2025) 1148
FIGURE 63 AMGEN INC.: COMPANY SNAPSHOT (2025) 1160
FIGURE 64 ASTRAZENECA: COMPANY SNAPSHOT (2025) 1167
FIGURE 65 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2025) 1181
FIGURE 66 BD: COMPANY SNAPSHOT (2025) 1204
FIGURE 67 CARDINAL HEALTH: COMPANY SNAPSHOT (2024) 1210
FIGURE 68 B. BRAUN SE: COMPANY SNAPSHOT (2025) 1214
FIGURE 69 TERUMO CORPORATION: COMPANY SNAPSHOT (2025) 1217
FIGURE 70 NIPRO: COMPANY SNAPSHOT (2025) 1221
FIGURE 71 STEVANATO GROUP: COMPANY SNAPSHOT (2025) 1224
FIGURE 72 GERRESHEIMER AG: COMPANY SNAPSHOT (2025) 1229
FIGURE 73 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2025) 1234
FIGURE 74 YPSOMED: COMPANY SNAPSHOT (2025) 1238
FIGURE 75 PHARMACEUTICAL DRUG DELIVERY MARKET: RESEARCH DESIGN 1246
FIGURE 76 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 1251
FIGURE 77 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 1252
FIGURE 78 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 1252
FIGURE 79 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 1253
FIGURE 80 MARKET SIZE APPROACH – REVENUE SHARE ANALYSIS 1254
FIGURE 81 REVENUE SHARE ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON (2025). 1255
FIGURE 82 TOP-DOWN APPROACH 1256
FIGURE 83 BOTTOM-UP APPROACH 1256
FIGURE 84 DEMAND-SIDE APPROACH 1257
FIGURE 85 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF PHARMACEUTICAL DRUG DELIVERY MARKET (2026–2031) 1258
FIGURE 86 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 1259
FIGURE 87 DATA TRIANGULATION METHODOLOGY

電力監視市場規模、シェア、動向、2031年までの世界予測前の記事水素エネルギー貯蔵市場規模、シェア、動向、予測、2026-2034年次の記事

Pharmaceutical Drug Delivery Market - Global Forecast to 2031

本レポートを購入する理由

本レポートは、以下のポイントに関する洞察を提供します。

Report Description

Research Coverage

Reasons to Buy the Report

This report provides insights into the following pointers:

Table of Contents

List Of Tables

List Of Figures

関連記事

経口タンパク質およびペプチド市場 – 2029年までの世界予測

世界のアンチエイジング製品市場予測 2025-2032年

感染管理市場規模、シェア、動向、2030年までの世界予測

世界のアンチエイジング製品市場予測　2025-2032年